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Summary
Questions about the emergence of life has fascinated humankind for all times.
On the basis of Darwin’s generally accepted theory of evolution, countless hy-
potheses try to explain the evolutionary progression. Especially the Origin
of Life, that is the formation and characteristics of the first ”living” unit,
sparks our interest.
In this work, I attempted to synthesize a possible precursor to the present-
day hereditary material (DNA) and to investigate its chemical and physico-
chemical properties. Today’s DNA consists of four different nucleotide build-
ing blocks, which are in turn subclassified into two categories: purines and
pyrimidines. A hypothesis, posited by Siegel and Tor, proposes a system
based on four pyrimidine bases whereof the present-day nucleic acids could
have arisen. One single building block could have been the source of these
four suggested nucleobases, whereas the two contemporary pyrimidine bases
C and U plus two yet unknown nucleotides D and E would pair in a Wat-
son/Crick -mode. D and E exhibit two exocyclic amino nucleotides (EANs)
possessing an exocyclic amino-glycosidic junction between the pyrimidine and
the sugar moiety (see Figure 1). As harbingers of A and G, respectively, D
and E should show similar chemical properties concerning strength of base
paring, as well as selectivity in binding of complementary bases.
In order to investigate and confirm these prerequisites, a model compound
of nucleotide D was synthesized and incorporated into oligonucleotides. Due
to problems of synthesis and stability, a homo-C analogue was chosen as
a model compound. Compared to EANs, a homo-C nucleotide features a
1
2more stable methylene-bridged glycosidic bond, but should be sterically and
electronically quite similar.
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Figure 1: Proposal of a DNA precursor.
I have been able to determine the base pairing properties of homo-C nu-
cleotide D qualitatively by DNA melting experiments of different comple-
mentary, double stranded oligonucleotides. The examinations demonstrated
that D has characteristics similar to its analog A and is able to bind U in
Watson/Crick -mode; however, the binding ability of D seems to be highly
dependent on its proximity. Presumably, strong dipole inducing flanking
bases are necessary to stabilize the flexible homo-C nucleotide D in a stacked
conformation. If this more or less stable stacking is assured, an effective
binding can be observed. Furthermore, the experiments showed that D binds
less selectively than its analog A. Stable pairings were observed with A and
G as complementary bases. This observation can be explained by possible
binding patterns.
Unfortunately, I have not been able to synthesize the G analog homo-C nu-
cleotide E and therefore I was unable to investigate an all-pyrimidine system.
Zusammenfassung
Die Entstehung des Lebens faszinierte die Menschheit und auch die Forschung
seit jeher. Basierend auf der allgemein anerkannten darwinschen Evolu-
tionstheorie versuchen unza¨hlige Theorien die evolutiona¨re Entwicklung zu
erkla¨ren. Speziell der Urspung des Lebens, die Bildung und Eigenschaften
der ersten ”lebenden” Einheit erweckt unser Interesse.
In dieser Arbeit wurde versucht ein mo¨glicher Vorla¨ufers der heutigen Erb-
substanz DNA zu synthetisieren und auf seine chemischen und physikalis-
chen Eigenschaften zu untersuchen. DNA besteht aus vier verschiedenen Nu-
cleotidbausteinen, die wiederum in zwei Kategorien unterteilt werden: Purine
und Pyrimidine. Eine Hypothese, aufgestellt von Siegel und Tor, schla¨gt ein
System aus vier Pyrimidinbasen vor, aus dem die heutigen Nucleinsa¨uren ent-
standen sein ko¨nnten.1 Die vier vorgeschlagenen Nucleobasen ko¨nnten alle
aus ein und demselben Grundbaustein hervorgegangen sein, wobei die zwei
kontempora¨ren Pyrimidinebasen C und U, sowie zwei bis dato unbekannte
Nucleotide D und E Watson/Crick–Basenpaarung eingehen wu¨rden. D und
E, zwei Nucleotide mit einer exocyclischen amino-glykosidischen Bindung als
Vorla¨ufer von A respektive G mu¨ssten a¨hnliche Eigenschaften bezu¨glich der
Sta¨rke der Basenpaarung sowie Selektivita¨t der Bindungspartner aufweisen
(see Figure 2).
Um diese Voraussetzungen zu untersuchen wurde in dieser Arbeit eine Modell-
verbindung des Nucleotids D synthetisch hergestellt und in Oligonucleotide
eingebaut. Auf Grund synthetischer Probleme wurde in der verwendeten
Modellverbindung die amino-glykosidische Bindung durch eine stabilere Me-
3
4thylenbru¨cke ersetzt. Das erhaltene homo-C Nucleotid sollte jedoch aus ster-
ischer und elektronischer Sicht eine gute Imitation darstellen.
N
NX
HN
O
H
O
PO2
O
N
NXO
O
PO2
O
H
O
R2O
O
O
R1O
O
PO2
O
N
N
O
O
H
N
N
O
NHH
D (A)
E (G) C
U
X = NH, CH2
Figure 2: Vorschlag eines mo¨glichen DNA Vorla¨ufers.
Durch DNA-Schmelzexperimente von verschiedenen komplementa¨ren, dop-
pelstra¨ngigen Oligonucleotiden konnten die Basenpaarungseigenschaften von
D qualitativ bestimmt werden. Es wurde gezeigt, dass D durchaus a¨hnliche
Merkmale wie die Purinbase A besitzt und U in Watson/Crick–Weise binden
kann. Allerdings zeigte D eine starke Abha¨ngigkeit seiner Nearest Neigh-
borhood, also der direkten Nachbarn in 5’- und 3’-Richtung. Vermutlich
sind stark Dipol induzierende Basen in der direkten Nachbarschaft no¨tig um
die flexible Nucleobase D in einer stacked Konformation zu stabilisieren und
dadurch eine stabile Basenpaarung zu ermo¨glichen. Weiter zeigten die Exper-
imente, dass homo-C Nucleotid D eine geringere Selektivita¨t als sein Analog A
aufweist und auch Bindungen zu A und G eingehen kann, was mit mo¨glichen
Bindungsstrukturen ra¨umlich erkla¨rt werden kann.
Leider gelang es uns nicht das G Analog homo-C Nucleotid E zu synthetisieren
und somit ein reines Pyrimidinesystem zu untersuchen.
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Chapter 1
Introduction
1.1 Chemical Evolution
The oldest procaryotic microfossils found are estimated to be 3–3.5 billion
years old.2 But what came before? How did such a diverse and complex
structure evolve on a unwrought planet? The detailed process of prebiotic
evolution is uncertain and must remain hypothetical because an unchallenge-
able proof for the primeval ”living unit” is not possible. Nonetheless, suppo-
sition about the nature of this historical event motivates modern biochemical
experiments, which lead to new discoveries.
First, one should define the term ”Life,” but opinions already differ on this
highly philosophical question. From a biomolecular point of view, the most
rudimentary definition of a ”living unit” requires only the capability of repro-
duction, sexually or asexually. This definition requires a system that stores
and imparts genetic information, and therefore maintains heredity. A more
general definition includes the requirements of adaptation, metabolism, and
growth and may involve, on a higher level, organization of several units.
Adaptation means the ability to change over a period of time in response
to environment, a quality which is fundamental to the process of evolution.
Metabolism is necessary for growth, but, hypothetically, not implicitly re-
9
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quired at an early stage of ”life” if building blocks for replication are avail-
able.
All present-day living organisms are based on the same system, in which De-
oxyribonucleic acids (DNA) contain the genetic information and Ribonucleic
acids (RNA) are transcribed from DNA and carry the code of single genes.
This information is then translated into peptides, the molecular machines of
cells. These three biopolymers are presumably intermediates of the develop-
ment toward present-day cellular mechanisms and one of these was possibly
even the first biopolymer. It is crucial to find out which biopolymers or
building blocks could have been available and stable under prebiotic condi-
tions and which evolutionary pathways could have led to the other elements
of the current system. The search for a prebiotic hereditary material can,
therefore, be limited to two questions:
– which of the following biopolymers was first: DNA, RNA or peptides?
– what are possible precursors of that biopolymer?
This discussion is hypothetical and is based on model systems because ques-
tions regarding conditions on early earth and the point in time when life
evolved must remain open. The latter can be only roughly estimated to be
∼4 billion years ago and this makes it difficult to determine the environment
at this time. Since the pioneering work of Haldane and Oparin, the prebiotic
soup theory has dominated the theories about how life emerged on earth.3,4
According to a modern version of this theory, organic compounds accumu-
lated in the primordinal oceans, underwent polymerization and generated
increasingly complex macromolecules.5 In general, the scientific community
agrees on assumed conditions like moderate pH, reducing atmosphere (lack of
O2) and aqueous ambience but one crucial controversial subject is the tem-
perature. One theory suggests that life originated at hydrothermal vents,
which is based on the fact that thermophilic microorganisms, which grow at
temperatures between 80 ◦C and 110 ◦C, are claimed to be the oldest organ-
isms known so far.6 But many experts doubt this theory due to temperature
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lability of biomacromolecules.7
Another motivation for intensive discussions is the dilution problem. Poly-
merization of available building blocks implies a fairly high concentration of
those monomers, a prerequisite which was not fulfilled in primordinal oceans.
Accumulation in small puddles or enrichment on mineral surfaces is consid-
ered to solve this problem.8 Minerals can also serve as templates for poly-
merization and crystallization.9 A second solution for the dilution problem
may be compartments, enclosure of simple building blocks or even simple
metabolisms in micelles.10
The importance of minerals is also a contended subject. In addition to their
ability to absorb organic compounds, they can also stabilize them in diverse
fashions (e.g. ribose is stabilized by borates11) or they can catalyze countless
reactions. Wa¨chtersha¨user proposed a highly regarded theory about surface
metabolism.12,13 He suggested that the first primitive metabolic system was
a series of reactions based on monomeric organic compounds made directly
from simple constituents (CO, CO2, NH3, H2S) in the presents of metal sulfide
catalysts and hot magmatic exhalations.14
CO-CO-CH3
H2S / CO
Fe, Co, Ni
Cluster /mineral
library
OC
CO
CH3
C CO
CH3
HO
O
HCO2H
H3C SHCO2
H3C CO2H
SCH3
CO
CH3
CO2H
CO
CH3
NH3
Ala
Peptide
library
Figure 1.1: Metabolism, catalyzed by sulfide clusters.
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Even though Wa¨chtersha¨user’s proposal describes only a metabolic circle
without any considerations about hereditary material, it could be an impor-
tant piece of the puzzle, helping us to explain how building blocks or even
biopolymers were synthesized under prebiotic conditions.
Another approach toward the formation of building blocks and biopolymers
is the famous experiment by Urey and Miller in 1953.15,16 They tried to sim-
ulate the atmosphere on primitive earth and exposed a mixture of H2O, CH4,
NH3, H2 and CO to electric discharges. Out of the product mixture, they
were able to isolate a series of organic compounds like formic acid, acetic acid,
glycine, alanine, urea et cetera. This discovery was a milestone in prebiotic
science, but some doubts were raised with respect to its accuracy. Probably,
the simulated conditions were too mild compared to locally distributed rough
conditions in the primal atmosphere. Additionally, the UV sensitivity of NH3
and CH4 could have also constituted a problem.
Figure 1.2: Apparatus of the Miller-Urey experiment.
Another crucial problem of chemical evolution science arose in Miller’s dis-
covery because he detected all amino acids as racemic mixtures. The origin
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of nature’s homochirality, why proteins and nucleic acids are composed of
predominantly L-amino acids and D-sugars is still uncertain. Several ap-
proaches try to explain homochirality in consequence of asymmetric auto-
catalysis, asymmetric catalysis by prebiotic amino acids which were enriched
in one of the enantiomeric forms, or enantiomeric adsorption on chiral min-
eral surfaces like quartz.17–21 Another theory by Mills proposes an early
racemic system, which evolved to a chiral one due to kinetic advantages of
the latter.22 It is known for example, that oligomerisation of monomers of
the same handedness polymerize faster. Summarized, all these theories point
to a spontaneous resolution of one of the enantiomers as likely.
1.1.1 The RNA World hypothesis
As mentioned above, searching for the prebiotic hereditary material leads to
the conclusion that either DNA, RNA, or peptides are possible candidates.
Its special function, and its importance in the cell’s metabolism, turned sci-
entist’s attention to RNA. Prestigious scientists like Francis Crick, Manfred
Eigen, Walter Gilbert and Leslie Orgel are regarded as the founders of the
RNA World hypothesis. Several facts count for RNA being the starting point
of the chemical evolution of our cellular metabolism. First, RNA is the con-
nection between genetic material and metabolism and, second, RNA was
found to have the ability to contain genetic information and some enzyme-
like catalytic activities. It’s obvious that RNA can hold genetic information
in the same fashion as DNA but the discovery of several enzymatic activities
in the 80’s of the last century was very surprising. Altman et al. discovered
RNA that acts as a coenzyme in ribonuclease23–25 and Cech et al. found ribo-
somal RNA containing a self-splicing exon.26–28 With these new insights, one
can hypothesize that RNA is able to participate in self-replication and recom-
bination.29 Accordingly, an RNA World can be contemplated that contains
only RNA molecules that served to catalyze the synthesis of themselves,30
and that developed a range of enzymic activities by using cofactors.31 Later,
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RNA could have begun to synthesize proteins followed by the appearance ini-
tially of single stranded DNA. Later, evolution of the complementary double
strand allowed stable linear information storage as well as error correction.
It seems reasonable to conclude that the RNA World did exist at some time
but many doubts have been raised about whether or not the primordial
hereditary material could have been RNA. In order to be a potential pre-
biotic biopolymer, it should be stable under primordial conditions, but, as
explained in section 3.3.2.7, RNA is labile to hydrolysis and to UV back-
ground radiation.32 Additionally, ribonucleic acid synthesis under prebiotic
conditions has not been successful in the laboratory so far.33
1.1.2 Possible Precursors of DNA/RNA
Due to the stability problems of RNA which were mentioned in section 1.1.1
and the consequential fact that the precise chemical nature of the original
genetic material presumably differed from present-day RNA the search con-
tinues for a possible precursor to RNA or DNA. Such a progenitor requires to
be stable and synthetically accessible under prebiotic conditions. A series of
candidates were suggested in the literature but only the most reasonable ex-
amples should be mentioned here. Concerning evolutionary mutations within
the nucleic acid structure, three parts can be examined separately: backbone,
sugar and base. As a backbone modification, Miller and Orgel suggested Pep-
tide Nucleic Acid (PNA) as a possible precursor of RNA.34 PNA consists of
AEG (N-(2-amino- ethyl)glycine) units, which were shown to be available
from CH4, N2, NH3 and H2O in electric discharge reactions.35 PNA binds
DNA and forms double and triple helical structures that are related to the
Watson-Crick helix.36,37
Another candidate was first prepared by Ueda in 1971: Glycerol nucleic acid
(GNA).38 This analogue also showed pairing to DNA and RNA as well as
self-pairing. Although it is composed of an acyclic three carbon backbone
unit, GNA exhibits stronger Watson-Crick pairing in duplex than its natu-
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ral counterparts. Furthermore, the building blocks should have been easily
available under prebiotic conditions.39–41
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Figure 1.3: Points of attack for possible mutations.
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Figure 1.4: Possible backbone precursors in comparison with DNA(RNA).
As seen in Figure 1.4, PNA units are, in contrast to present-day nucleic
acids, connected by amides. Another crucial question of chemical evolution
sciences is, why nucleosides are connected by phosphodiester groups? In
1987, Westheimer discussed the advantages of phosphodiesters holding sugar
units together in RNA and DNA42 and a pioneering study by Usher dealt the
question of why the junction is positioned between carbons 3’ and 5’ instead
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of 2’ and 5’. He found experimentally the (2’→5’) junction to be more sus-
ceptible to hydrolytic strand cleavage.43,44
Albert Eschenmoser systematically studied many possible sugar modifica-
tions.45–49 He asked why nature developed the structure type of ribofuranosyl
nucleic acids, rather than some other sugar family, and prepared nucleic acid
systems with several different sugar moieties. He found the capability of
Watson-Crick base-pairing to be a widespread property among potentially
natural nucleic acid alternatives. The most promising systems were the so-
called homo-DNA and TNA.45,49,50
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Figure 1.5: Structure of two different Homo-DNA’s and TNA.
He uses the term ”homo-DNA” for an artificial oligonucleotide system differ-
ing from DNA in an expanded six-membered pyranose ring by an additional
methylene group. Due to its chemical composition, homo-DNA was never
supposed to be a potentially natural nucleic acid alternative but it showed
much stronger Watson-Crick base pairing than DNA itself, presumably a
consequence of the higher rigidity of pyranose rings, compared to those of
furanose.51 An constitutional isomer of homo-DNA was investigated by Van
Aerschot et al. (see Figure 1.5, middle). He linked the base to the sugar
at carbon 2’ and prepared oligonucleotides, which show strong Watson-Crick
base pairing and additional cross pairing to RNA.52
Even more surprisingly was the discovery of pairing abilities of TNA ((L)-α-
THREO-furanosyl-(3’→2’)-oligonucleotides). Eschenmoser et al. prepared
these tetrose sugar units, containing only five covalent backbone bonds per
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repeating unit, which show efficient base pairing similar to canonical RNA
with regard to specificity, strand orientation and pairing strength.50 In ad-
dition, (L)-TNA oligonucleotides are capable of cross-pairing with RNA and
DNA, which is remarkable when one considers the constitutional and con-
formational differences between these polymers. Furthermore, TNA is much
more stable toward hydrolytic cleavage of the phosphodiester linkage than
RNA and could be presumably formed under prebiotic conditions from gly-
colaldehyde.53
A third site for evolutionary modifications is the base. The instability of
nucleobase C (see section 3.3.2.7), which shows on the geologic timescale a
very short half-life for the decomposition, even at 0◦C, raises the question
of whether it would have been a suitable base for the first genetic material.
Suggestions for a prebiotic harbinger of a present-day complementary base
system are rare, but a series of alternative bases and base pairs have been
proposed. For example, Benner et al. suggests isoguanine (isoG) and isocy-
tosine (isoC), diaminopurine (amino A) and U or pseudo-diaminopyrimidine
(pseudo D) and xanthine.54 Another proposal was published by Miller et al.:
A and 1,2,4-triazole-3,5-dione (urazole).55
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Figure 1.6: Alternative base pairs for GC.
Wa¨chtersha¨user proposed an all-purine system (Figure 1.7).56 His assump-
tion is motivated by the fact that purines can be oligomerized on a com-
18 CHAPTER 1. Introduction
plementary template in the absence of polymerase. But pyrimidines cannot,
probably because of low stacking energies.57 Furthermore N3 bound purines
have been found in prokaryote and eukaryote cells.58,59
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Figure 1.7: Proposed binding pattern of an all-purine system.
A completely opposite proposal was posted by Siegel and Tor: an all-pyrimidine
precursor (Figure 1.8).1 They postulate a possible precursor to be compati-
ble with the present system, but less fit for the environmental pressures that
motivates mutational evolution. It should be isosteric with the modern code
and accessible from a single progenitor heterocycle. Such a progenitor could
be 2,4-diaminopyrimidine, which was presumably available on prebiotic earth
and can be converted by hydrolysis to C and U (see section 3.4.1). By un-
equal formation of the glycosidic bond, a four letter code containing only
these three pyrimidine bases can be assumed as outlined in Figure 1.8. A
detailed discussion about this system will follow in the next chapter.
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Chapter 2
The Project
As mentioned before, Siegel and Tor published a proposal of an all-pyrimidine
precursor of DNA or RNA (see section 1.1.2, Figure 2.1).1
N
NHN
HN
O
H
O
PO2
O
N
NHNO
O
PO2
O
H
O
R2O
O
O
R1O
O
PO2
O
N
N
O
O
H
N
N
O
NHH
D (A)
E (G) C
U
Figure 2.1: DNA/RNA precursor based on pyrimidines.
Based on the knowledge that cytosine (C) is the least stable of the four
present day nucleobases and undergoes spontaneous hydrolysis to uracil (U)
(see section 3.3.2.7) one can assume cytosine to be a hydrolysis product of
2,4-diaminopyrimidine (D) (Figure 2.2). With these three pyrimidines, one
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can draw a pattern consisting of the known nucleosides C and U and two un-
known nucleosides building the glycosidic bond through an exocyclic amino
group. Nucleoside D would be isosteric to adenosine (A) and E would be isos-
teric to guanosine (G), each forming a motif with two hydrogen bonds. From
an evolutionary point of view, these exocyclic amino nucleosides (EANs)
could be harbingers of A and G, respectively. EANs are not only hypothet-
ical constructs. They are also known in nature as degradation products of
purines under oxidative pressure60 or natural metabolites.61 Especially the
fact that purines degrade under oxidative stress is of interest. Assuming a
strongly oxidative atmosphere, purines would not be existent in the absence
of a repairing system, but EANs would. Therefore its quite reasonable to
propose EANs as harbingers of present-day purines. A few examples of nat-
urally occurring EANs will be illustrated in section 3.4.
The aim of this thesis is to investigate and possibly support this hypothesis
chemically. Therefore, building blocks should be synthesized to investigate
their stability and physicochemical properties. Additionally, oligonucleotides
containing this artificial nucleotides are of interest to determine their ability
of base pairing in a Watson-Crick mode.
A summary of conditions that an all-pyrimidine system should fulfill to be a
possible precursor of the contemporary hereditary material is listed bellow.51
Some of these conditions are difficult to prove and will not be a target of this
project; however, they should be investigated in the future.
– accessible from simple molecules available on primitive earth
– available by the same type of potentially natural chemistry that allows
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the structure of RNA to be derived from ribose
– capable for informational base pairing in the Watson-Crick mode
– able to self-replicate non-enzymatical under potential conditions
– able to express a chemical phenotype in the given environment
Preliminary studies performed in our laboratory62,63 and by others64 have
shown EANs to be susceptible to anomerisation, deglycosylation, and iso-
merisation. The presence of strong electron-withdrawing substituents on the
pyrimidine ring can diminish these problems, but such a modification would
obviously change pyrimidine’s electron density and therefore its ability for
base pairing. To avoid this restriction, we decided to switch to carbon ana-
logues, where the glycosidic bond is formed through a bridging methylene
group instead of an exocyclic amino function. Greenberg et al. showed such
C-nucleosides to be useful models.65 These so-called homo-C nucleosides
should be thermodynamically more stable than the corresponding EANs,
sterically comparable and in addition not dramatically different concerning
electron density, as shown by Berstis.66
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Figure 2.3: Homo-C analogs of nucleosides D and E.
Chapter 3
State of Knowledge
3.1 Historical Overview
At the time when Charles R. Darwin67 (1859) and Gregor Mendel68 (1866)
published their famous theories, the chemical knowledge about processes in
living organisms was very rudimentary and limited to the physical dimen-
sion of cells. General opinion, of the time, considered genes to be proteins,
because proteins were the only biochemical building blocks one estimated
to exhibit the necessary specificity. Ernst Haeckel69 proposed in 1866 that
the Nucleus contains the factors responsible for the transmission of heredi-
tary traits and only three years later, in 1869, Friedrich Miescher discovered
DNA by observing a precipitate from a leucocyte extract under acidic con-
ditions.70,71 He noticed that this leucocyte extract, obtained from pus on
fresh surgical bandages, contained a substance which precipitated when acid
was added and dissolved again when alkali was added. Due to its presence
in the nuclei, Miescher termed the enigmatic compound ”nuclein”. Later he
was able to show that nuclein, unlike proteins, lacked sulfur but contained a
large amount of phosphorus.72 Although neither the structure nor the exact
function of this new substance was yet known, Walther Flemming73 described
the morphology and behavior of the chromosomes during mitosis and, only
one decade later, Theodor Boveri74 made the case that the chromosomes not
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only harbor the genetic information, but that individual chromosomes carry
different parts of the hereditary material.
Within two decades, from 1909 to 1929, Phoebus Levene characterized RNA
and DNA, identified the four DNA builing blocks A, C, G and T and formu-
lated the tetranucleotide hypothesis, based on the fact that he had found the
four building blocks in equal ratios. On the basis of this hypothesis he pos-
tulated a monotonously repeating sequence, which consequently would not
be able to have genetic function (see Figure 3.1).75
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Figure 3.1: Hypothetical tetranucleotide, as proposed by Levene.
Approximately at the same time, Frederick Griffith postulated the trans-
forming principle.76 He observed that a mixture of heat-killed virulent S
pneumococci (Diplococcus pneumoniae) and non-pathogenic R pneumococci
is still contagious, both in vivo and in vitro. He concluded that a transfor-
mation of R to S occurred, induced by the disarmed S pneumococci. The
nature of this transformation remained unclear until Oswald Avery, Colin
MacLeod and Maclyn McCarty showed DNA to be the transforming princi-
ple, in 1944.77 They reported this principle to have all physical and chemical
properties of DNA. It contained no detectable proteins, was unaffected by
trypsin, chymotrypsin and ribonuclease, but was completely inactivated by
DNase.
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Unfortunately, McCarty’s insight remained unappreciated until 1949 when
Erwin Chargaff determined the accurate ratios of nucleobases in DNA and
disproved the tetranucleotide hypothesis. Thereby he indicated that DNA
could be complex enough for a potential genetic function;78 however, decisive
evidence was found by Ralph Brinster et al. three decades later!79 Brinster’s
team proved that DNA is also the transforming principle in eukaryotes by
injection of DNA bearing the gene for rat growth hormone into in-vitro fer-
tilized mouse eggs and implantation of those into the reproductive tracts of
foster mothers. The resulting transgenic mice had high levels of rat growth
hormone in their serum and reached nearly twice the size of their natural
littermates.
From the perspective of structural analysis of DNA, the first momentous
breakthrough was accomplished by the two teams Franklin–Wilkins and Watson–
Crick, with the clarification of the helical structure.80–82 Franklin and Wilkins
demonstrated that DNA has a regularly repeating helical structure, and Wat-
son and Crick discovered the molecular constitution of DNA. They found the
later to be a double helix in which A always pairs with T, and C always with
G. Additionally, Crick proposed four years later the translation of informa-
tion in DNA into proteins through RNA and he speculated that one amino
acid in a protein is always coded by three bases in DNA.83
Two other milestones in the history of DNA should be mentioned here:
1) In the late 1970s several methods to sequence DNA were developed by
Frederick Sanger, Allan Maxam and Walter Gilbert.84,85
2) In 2001 the complete sequence of the human genome was puplished.86
3.2. Biological Function of Nucleosides 25
3.2 Biological Function Of Nucleosides, Nu-
cleotides and Nucleic Acids
Nucleotides are biologically ubiquitous substances. In addition to their cen-
tral role in both storage and expression of genetic information, they partici-
pate in many biochemical processes.87 In this section only a short overview
of biological functions of nucleosides should be outlined. In respect of the
widespread biological activities of nucleosides, analogs, as synthesized in this
thesis, are always of interest to be tested in biochemical studies. Section 4.7
will summarize possible application fields of nucleoside analogs and therefore
the biochemical background should be discussed here.
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Figure 3.2: Nucleotide coenzymes NAD+, NADP+, FAD and CoA.
The most widespread and probably most investigated derivatives of nucleo-
sides are ATP or nucleoside triphosphates in general. Since ATP was dis-
covered in 1929 by Karl Lohmann88 it has been recognized as an energy
source for many important reactions and cells have complex mechanisms for
its synthesis. More recently, ATP (and/or ADP) was found to influence many
biological processes like platelet aggregation, vascular tone, neurotransmis-
sion, cardiac function and muscle contraction.89 Nucleotide derivatives, such
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as nicotinamide adenine dinucleotide (NAD+, NADP+), flavin adenine dinu-
cleotide (FAD) or coenzyme A (CoA), are known to serve as coenzymes (see
Figure 3.2).
In 1982, Cech et al. demonstrated that some RNAs undergo autocatalytic
rearrangements, also called splicing.26 They drew the conclusion that RNA
cleavage and ligation activity are intrinsic to the structure of the molecule.
Furthermore, RNA was also found to act as a coenzyme in RNA-dependent
DNA polymerase, for instance.90,91
3.3 DNA Structure
3.3.1 Nucleosides and Nucleotides
Nucleic acids can be divided into two main classes: Ribonucleic acids (RNA)
and Deoxyribonucleic acids (DNA). Their building blocks, called nucleotides,
are composed of a nucleobase, a sugar moiety and a phosphate group. They
differ foremost in the sugar moieties, which are the pentose sugars D-ribose
in RNA and 2-deoxy-D-ribose in DNA.
Both classes of nucleic acids consist of four building blocks, which can again
be subdivided into two categories: purines and pyrimidines. The purine
nucleotides adenosine (A) and guanosine (G) as well as the pyrimidine nu-
cleotide cytidine (C) appear in both RNA and DNA. By contrast, the re-
maining pyrimidine nucleotide is found in RNA as uridine (U) and in DNA
as thymidine (T, 5-methyluridine).
The pentose sugar is locked in a five-membered furanose form, linked to the
nucleobase at C1’. This so-called glycosidic bond is on the same side of the
sugar as the C4’–C5’ bond and is termed to be in a β-configuration (R vs.
α-configuration, which is S). The phosphate group may be bonded to the 5’-
(5’-nucleotide) or to the 3’-hydroxy group (3’-nucleotide). In the absence of
a phosphate group the unit is called a nucleoside. In Figure 3.3, all of these
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five nucleosides are shown, including atom numbering and nomenclature of
nucleobases (e.g. adenine) and nucleosides (e.g. adenosine), following the
recommendation of IUPAC CBN.92
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Figure 3.3: Structures of the five major nucleosides in DNA and RNA.
3.3.2 Physical Properties of Nucleosides and Nucleotides
3.3.2.1 Protonation
For a better understanding of the detailed structure and hydrogen bonding
ability of DNA, RNA, and their constituents, it is crucial to know exactly
the sites and thermodynamic quantities associated with the interaction with
protons. For example, protonation plays an important role in determining
the base form available for base pairing and recognition in macromolecular
structures because a protonated nucleobase has obviously other hydrogen
bond acceptor and donor abilities than it’s neutral counterpart.93
As seen from the pKa values all bases are uncharged in a pH range of 5–9
(Table 3.1). The phosphodiester group has a pKa value of ∼ 2.6 (H3PO4:
pKa1 = 2.15). In former times, it was stated that ionization of A, G and
C occurs at the exocyclic amino group, which is comprehensible due to the
greater electron density on exocyclic, rather than ring nitrogens. However, it
was later concluded that the most basic site is not necessarily determined by
the highest electron density, but rather by the conditions in the protonated
state.95 That means in other words, the better the protonated species is
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Table 3.1: pKa values for bases in deoxy-nucleosides and -nucleotides (conc.
5−5 – 10−5 M, 20 ◦C, zero salt conc.).94
Base, site of protonation Nucleoside 5’-Nucleotide 3’-Nucleotide
Adenine N1 3.5 3.9 3.7
Guanine N7 3.3 – –
N1 9.4 10.0 9.8
Cytosine N3 4.2 4.6 4.4
Thymine N3 9.9 10.5 –
Uracil N3 9.4 10.1 10.0
stabilized by resonance structures, the more basic is the corresponding pro-
tonation side. This finding led to the conclusion that in adenine, for example,
N1 is the most likely site of protonation, which was confirmed by calculations,
X-ray and NMR.96–98
For the sake of completeness it should be mentioned here that the 2’-OH of
ribonucleosides and their corresponding 3’-monophosphates were also inves-
tigated. The pKa values of the 2’-OH group of A, G, U and C were found to
be 12.2, 12.5, 12.6 and 12.5, respectively. In addition, the pKa values for the
3’-monophosphates of AMP, GMP, UMP and CMP are 13.4, 13.5, 13.6 and
13.6, respectively.99
3.3.2.2 Tautomerism of Bases
Nucleobases, regardless if present as nucleotides, nucleosides or as simple
heterocycles without a sugar entity, exist in solution in an equilibrium of
tautomers. The concentration of the preferred tautomer usually exceeds
that of the others by a factor of 103–106.100 This predominance of one ma-
jor tautomer is absolutely essential, because tautomers show different hy-
drogen bonding donor/acceptor properties (D/A) and can, therefore, form
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non-Watson/Crick base pairs (Scheme 3.4). Such non-Watson/Crick base
pairs could lead to point mutations if they are not detected by repair en-
zymes.101–103 The predominance of one major tautomer is also necessary to
ensure a correct recognition of complementary bases, which is the quintessence
for DNA replication and transcription.
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3.3.2.3 Sugar-Phosphate Chain Conformation
Considered superficially, one could expect nucleic acids to be very flexible,
due to all possible bond rotations defined in Figure 3.5a as torsion angles α,
β, γ, δ, ε, ζ and χ. But, these seven torsion angles are subjected to many
intramolecular restrictions, which make the structure much more rigid than
estimated. Starting the analysis with χ, the torsion angle of the glycosidic
bond, it is obvious that only two orientations of the base are sterically rea-
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sonable: syn and anti conformations (see Figure 3.6). In most double helixes,
only anti conformers are found in both purine and pyrimidine nucleotides.
An exception is Z -DNA, where purines adopt the syn orientation.
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Figure 3.5: Degrees of freedom in sugar and phosphate backbone.
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The flexibility of the sugar-phosphate backbone is limited as well. As shown
by Sundaralingam,104 bond rotations in the backbone chain are confined by
covalent stiffness of the ribose as well as non-covalent interactions of the
phosphate group. Nevertheless, the sugar-phosphate angles in double helix
are conformationally quite strain-free.
Only two envelope conformations are found in nucleosides and nucleotides:
C2
′
-endo and C3
′
-endo (Figure 3.5b). Endo refers to the case where the C2
′
or C3
′
sticks out of the plane to the same side as C5
′
. According to quantum-
chemical results, these two conformations undergo rapid equilibrium with a
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barrier of ca. 24 kJ/mol.105 B -DNA occurs only as C2
′
-endo ribose and A-
DNA only as C3
′
-endo. In contrast Z -DNA pyrimidine nucleotides are present
as C2
′
-endo riboses and purine nucleotides as C3
′
-endo.
3.3.2.4 Primary and Secondary Structure of DNA
Already twenty years before the helical structure of DNA was found, Klein
and Thannhauser described the primary structure of nucleic acids.106,107 They
established that the nucleosides are joined in a 5’→3’ manner by a phospho-
diester junction and that there are neither 5’–5’ nor 3’–3’ linkages. This
observation is evidence that the uniqueness of a DNA sequence resides only
in the succession of its bases.
Watson and Crick 81 deduced the helical secondary structure of B -DNA in
1953 from fiber diffraction patterns and in the same year Franklin and Gosling
reported the discovery of A-DNA.108 Franklin and Gosling also deduced from
their observation that a conversion between B -DNA and A-DNA should be a
reversible conformational change, which is dependent on the relative humidity
and the nature of the present cations. In 1979, a third example of secondary
structure was discovered. Wang and Rich found a left-handed double helix
and termed it Z -DNA.109 Table 3.2 summarizes the structural characteristics
of these three main occurrences of DNA.
At the time when Watson and Crick determined the helical structure of
DNA they had only cell extracts and, therefore, crystals of poor quality
available. It took another three decades until the first X-ray crystal struc-
ture at near-atomic resolution was published. In 1980, Dickerson et al. were
able to measure an X-ray with 1.9 A˚ resolution of an artificially synthe-
sized oligonucleotide (dGlc[CGCGAATTCGCG]).110 This was the first single-
crystal structure analysis of more than a complete turn.
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Table 3.2: Structural characteristics of A-, B- and Z -DNA.87
A-DNA B-DNA Z -DNA
Helical sense of rotation right-handed right-handed left-handed
Diameter ∼ 26 A˚ ∼20 A˚ ∼18 A˚
Base pairs per helical turn 11.6 10 12 (6 dimers)
Helical twist per base pair 33◦ 36◦ 60◦ (per dimer)
Helix pitch (rise per turn) 28 A˚ 34 A˚ 45 A˚
Helix rise per base pair 2.6 A˚ 3.4 A˚ 3.7 A˚
Base tilt normal to the
20◦ 6◦ 7◦
helix axis
Major groove
narrow and wide and
flat
deep deep
Minor groove
wide and narrow and narrow and
shallow deep deep
Sugar pucker C3
′
-endo C2
′
-endo
C2
′
-endo for pyrimidines
C3
′
-endo for purines
Glycosidic bond anti anti
anti for pyrimidines
syn for purines
3.3.2.5 DNA Duplex Stabilization
Since Watson and Crick presented their structural proposal of DNA,81 the
non-covalent interactions which influence the oligonucleotide duplex have
been investigated intensively.111,112 Some forces, including base stacking and
dipole-dipole interactions are stabilizing and other forces destabilize the du-
plex, such as electrostatic repulsion of the phosphates. Overall, DNA double
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helices are strongly favored enthalpically and are disfavored nearly as much
entropically.113 Rapidly, it became clear that hydrogen bonding is essential
for specific base pairing and ensures the reliability of DNA replication, but
makes only a small contribution to duplex stabilization.105 The main factors
for the latter are base stacking, dipole-dipole as well as hydrophobic inter-
actions. In 1964, Steward and Jensen described base stacking of adenine by
X-ray crystallography114 and showed a partial overlapping, which is charac-
teristic for the association of bases in crystals and in double helical nucleic
acids. Several noncovalent forces play a role in base stacking. Van der Waals
dispersive forces (dipole–induced dipole and induced dipole–induced dipole
attractions), permanent electrostatic effects of interacting dipoles, and solva-
tion effects influence the stacking stability.115 In general, the purines stack
more strongly than the pyrimidines, presumably because they have larger
surface area and greater polarizability. Kool et al. measured the stacking
free energy of natural bases as dangling ends in a short DNA duplex with a
C–G base pair at the end to be 0.5, 0.6, 0.7 and 1.0 kcal/mol for C, T, G and
A, respectively.116 But it needs to be considered that this stacking energy is
strongly dependent on its nearest neighboring bases, an influence called the
Nearest-Neighbor Effect.117 Recent studies have established that the stacking
of DNA and RNA bases is a strong contributor to the overall stabilization of
the double helix, and may be the dominant one.112
As already mentioned, hydrogen bonding does not play a crucial role in DNA
stabilization, but dipole–induced dipole interactions do. The strong dipole
of C induces another strong dipole in its easily polarizable complementary
Watson/Crick–base G, for example, and leads to a binding between the two
stands.118 The same effect occurs in T–A base pairs in a diminished man-
ner. Ionic interactions affect the duplex stability significantly. Electrostatic
repulsion of the anionic phosphate groups destabilizes the double helix but
can be degradated by cations, whereas divalent cations like Mg2+, Mn2+ or
Co2+ shield the phosphate groups much more effective than Na+ or K+.119,120
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3.3.2.6 Hydrogen Bonding Motifs
In addition to the Watson-Crick base pairs, 26 alternative mispairs for A, G,
U (T) and C, involving at least two hydrogen bonds, are structurally possi-
ble.105 In this chapter, we will only describe the biochemically most relevant
non-Watson-Crick base pairing motifs.
In 1963, Karst Hoogsteen heated a solution of adenine and thymine and then
let it cool slowly to form crystals. He found that in his crystals, adenine and
thymine did not form hydrogen bonds as proposed by Watson and Crick.121
Instead, they formed two hydrogen bonds, that involved the N7 atom of the
purine ring rather than the N1 atom. The Hoogsteen geometry is the most
favourable one for A–T base-pairs in solution, but not in double helices.
G–C base pairs can only form Hoogsteen base pairs if the cytosine N3 is pro-
tonated. Hoogsteen base pairing can be seen in three-dimensional structures
of transfer RNA, in triple-stranded helices when a third stand winds around a
duplex that is assembled in the Watson-Crick pattern or in G-quadruplexes,
where this alignment allows assembly of planar quartets which are composed
of stacked associations of Hoogsteen bonded guanines (see Scheme 3.8).122
Watson-Crick and Hoogsteen pairing can also occur in a reversed manner,
where one base is rotated by 180◦ with respect to the other. Reversed Hoog-
steen is found to be especially important in tRNA function.123
Another important hydrogen bonding motif was found by Francis Crick in
1966: the Wobble configuration.124 The G–U wobble base pair is a fundamen-
tal unit of RNA secondary structure that is present in nearly every class of
RNA. It has thermodynamic stability that is comparable to Watson-Crick
base pairs and is nearly isomorphic to them. Therefore, it often substitutes
for G–C or A–U base pairs.125
3.3. DNA Structure 35
R
O
H
H
H RO
H
H
R
RO
H
OH
H
Watson - Crick
R
H
OH
H
R
O
reversed Watson - Crick
R
H H
O
HO
R
R
H H
O
HO
R
Hoogsteen
reversed
Hoogsteen
R
HO
R
O
H
H
H
H
GC
+
 -
Hoogsteen
R
O
H
H
H
RO
H
H
H
Wobble
G C A T
A T
AT AT
GC
+
G C
Figure 3.7: Simplified non-Watson-Crick bonding motifs.
N
NH
NN
O
H2N
R
N
HN
N
N
O
H2N
R
N
HN
N N
O
NH2
R
N
NH
N
N
O
NH2
R
Figure 3.8: G-Quadruplex motif.
36 CHAPTER 3. State of Knowledge
3.3.2.7 Stability of Nucleobases, Nucleosides and Nucleotides
In terms of stability, there are three parts of the DNA structure that are
susceptible to spontaneous decomposition or cleavage in the cellular environ-
ment: the nucleobase, the glycosidic bond and the phosphodiester. Especially
in terms of chemical evolution, the stability of present-day nucleobases is of
interest. High temperature conditions for the origin of life is widely favored
among experts because hyperthermophiles, which are claimed to be the oldest
organisms on earth, grow at temperatures between 80 ◦C and 110 ◦C.6,126–128
M. Levy and S.L. Miller investigated the stability of nucleobases at various
temperatures and collected the following data (Figure 3.9, Table 3.3).129
Figure 3.9: Arrhenius plot for decomposition of A, U, G, C and T (pH = 7).
The most frequent kind of decomposition of nucleobases is deamination. Cy-
tosine can be converted to uracil by hydrolysis, adenine is converted to hy-
poxanthine and guanine to xanthine (see Scheme 3.10).130
The deamination of A and G is approximately 50-fold slower than those of
C,131 but, in view of absolute rates, the environment plays a crucial role. At
37 ◦C, the half-life (t1/2) of cytidine in single-stranded DNA is ca. 200 years,
which is quite similar to free cytosine, whereas in double-stranded DNA, it is
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Table 3.3: Half-lives of nucleobases in aq. solution (conc. 10−3 M, 0.05 M
phosphate buffer, pH = 7).
Temperature A G U T C
100 ◦C 1 yr 0.8 yr 12 yr 56yr 19 days
25 ◦C 1×104 yr 1×104 yr n.a. n.a. 340 yr
0 ◦C 6×105 yr 1.3×106 yr 3.8×108 yr 20×108 yr 1.7×104 yr
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Figure 3.10: Deamination of C, A and G.
on the order of 30,000 years. This observation means that the deamination of
C is 150-fold slower in duplex DNA and therefore strongly dependent upon
tertiary structure.132
Deamination plays an important role in mutagenesis. For example, the hy-
drolytic deamination product of adenine, hypoxanthine, forms a more stable
base pair with C than with T and needs to be removed by DNA repair mech-
anisms. The same is necessary for the cytosine hydrolysis product. The
deamination of C plays a central role in this thesis and will be discussed in
details in section 3.4.1. A remarkable fact should be mentioned here to show,
how a marginal structural change can influence the stability of a nucleobase
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and its biochemical relevance: 5-methylcytosine, a naturally occuring deriva-
tive of C, which constitutes 3% of DNA cytosine residues in mammalian cells,
is deaminated three to four times more rapidly than cytosine. This relatively
small difference is by itself unremarkable, but an inefficient DNA repair mech-
anism results in a dangerous mutagenic lesion.133
In addition to deamination, a few other endogenous damages are known.
Oxidation plays an important role in mutagenic lesions. The prevalent dam-
ages are oxidation of guanosine to 8-oxoguanosine and Fapy·dG (an imidazole
ring-opening product, which will be explained in details in section 3.4).
Another cause for DNA damage in living cells is nonenzymatic DNA methy-
lation, for instance. S-adenosylmethionine (SAM; a cofactor in enzymatic
transmethylation reactions) or other methyl donor agents are present in the
cell nucleus and act as endogenous genotoxic agents.134
Regarding the stability of nucleosides and (oligo-)nucleotides, the N-glycosidic
bond is a vulnerable point of attack. The hydrolytic release of free base was
found to be a function of temperature, pH, ionic strength and nucleic acid
secondary structure.135,136 Generalized purine nucleotides were found to lib-
erate the nucleobase 20-fold more rapidly than pyrimidine nucleotides. The
velocity of depurination differs in single-stranded and double-stranded DNA
only fourfold, Which means that the helical structure doesn’t provide much
protection. The influence of ionic strength was described to be marginal.
The difference between DNA and RNA, due to only one hydroxy group, is
tremendous. On one hand the 2’-OH group stabilizes the N-glycosidic bond
in RNA compared to DNA, but, on the other hand, it makes the phospodi-
ester much more susceptible. The RNA phosphodiester bond is very frail
to hydrolysis, particularly in the presence of base and/or divalent cations
(Mg2+, Ca2+, Zn2+).137
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3.4 Exocyclic Amino Nucleosides (EANs)
Exocyclic amino nucleosides (EANs) are known in nature as well as in synthe-
sis, but there is only a marginal knowledge about their biological significance
and activity as drugs. EANs were found as decomposition products of purine
nucleosides, as a fungal metabolite, as well as intermediates in the degrada-
tion metabolism of guanosine.61,138,139 A few examples were investigated as
antitumor and antiviral drug candidates due to their ability to mimic purine
nucleobases.140,141
Fapy·dA and Fapy·dG are degradation products of dA and dG, for instance.
These formamidopyrimidine lesions are produced in DNA as a result of oxida-
tive stress and have been implicated in mutagenesis.142–147 Purine nucleotides,
dG especially due to their low oxidation potential, are sensitive to oxidative
stress because a formal addition of a hydroxyl radical (or singlet oxygen 1O2)
can lead to opening of the imidazole ring (Scheme 3.2). The specific details of
the mechanisms for the formation of these lesions are uncertain.64 It has also
been shown that oxidative degradation of dG can lead to two other EANs:
dZ and dlz. Although the mechanisms of these lesions are not certain yet,
the damage seems to be a consequence of oxidation of dG to a guanine rad-
ical cation (dG•+) resulting in 2-aminoimidazolone (dlz) and its hydrolysis
product, oxazolone (dZ) as seen in Scheme 3.3.138
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EANs can also be found in natural product biosynthesis. Clitocine, a sec-
ondary fungal metabolite, is probably the most investigated EAN and was
isolated from the mushroom Clitocybe inverse.61,148 Clitocine (6-amino-5-
nitro-4-(β-D-ribofuranosylamino)pyrimidine) is an inhibitor of adenosine ki-
nase and shows strong insecticidal activity and an intense cytostatic effect
towards several leukemia cell lines.149
Another pyrimidine EAN found in nature is 2-(hydroxy/amino)-6-hydroxy-5-
(N-methyl-N-formylamino)-4-(D/L-ribofuranosylamino)pyrimidine.139 This
EAN seems to be a metabolic intermediate of guanosine degradation toward
derivatives of folic acid (see Figure 3.11).
Only a few artificial EANs are reported in the literature, such as exocyclic
amino pyrimido[5,4-d]pyrimidines140,141 and triazine nucleosides.63 The 4-
substituted 8-(Deoxy-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidines show
antitumor and antiviral properies (Fig. 3.12).
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3.4.1 Hydrolysis of 2,4-Diaminopyrimidine and Cyto-
sine
The fundamental idea behind this project is based upon the fact that 2,4-
diaminopyrimidine (D) can be converted to cytosine and further to uracil by
hydrolysis (see Fig. 3.13b). 2,4-diaminopyrimidine was presumable available
on prebiotic earth and could act as source of cytosine and uracil. Possible
syntheses of 2,4-diaminopyrimidine under prebiotic conditions were reported
by Miller from guanidine hydrochloride and cyanoacetaldehyde150 and by
Shapiro from cyanat and cyanoacethylene.151 Levy and Miller investigated
the hydrolysis of D in detail.129 As expected, they observed a mixture of
cytosine and iso-cytosine from the first deamination step as well as fully
hydrolyzed uracil. The half-life of D was found to be t1/2 = 42 days at 100
◦C and 40,000 yr at 0 ◦C. These hydrolysis rates are about the same as those
of cytosine (t1/2 = 19 days at 100
◦C, t1/2 ≥ 106 yr at 0 ◦C) and are fast on a
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geologic time scale. This fact indicates that D and C would be excluded from
use in a high-temperature origin of life. Additionally, other factors could
affect the rates of hydrolysis, such as the presence of other compounds in the
prebiotic soup. The deamination of cytosine to uracil, for example, has been
shown to be catalyzed by sulfite152 and other nucleophiles may act similarly.
Summarized, these facts point to a low-temperature origin of life.
(a) Arrhenius plot for the decomposition of D (pH = 7)
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(b) Hydrolysis of D
Figure 3.13: Diamination of 2,4-diaminopyrimidine.
3.4.2 Reactivity of EANs
The inertness of EANs was investigated in the case of formamidopyrim-
idines64,153 and exocyclic amino triazine nucleotides (EATNs).63 As seen in
Scheme 3.14, EANs can undergo acid-induced anomerisation, isomerisation
to the pyranose form, and hydrolysis (deglycosylation).
Greenberg et al. investigated Fapy·dA/dG lesions concerning epimerisation
and deglycosylation, respectively.64 For a monomeric Fapy·dA nucleoside,
they observed anomerisation of an α/β 1:1 mixture in phosphate buffer (10
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Figure 3.14: Anomerisation, isomerisation and hydrolysis of EANs.
mM, pH = 7.5, rt) shifting the ratio to α/β 1.33:1 within 6 h. Deglycosy-
lation occurred in the same buffer system as well. Temperature dependent
deglycosylation was determined for Fapy·dA and Fapy·dG in the monomeric
form as well as incorporated into single stranded DNA (ssDNA). Cleavage
rates under alkaline conditions (0.1 M NaOH) for monomeric nucleoside and
ssDNA were determined to be in the same range. Fapy·dG has a half-life
in the range of days, whereas Fapy·dA has a half-life in the range of weeks
(Table 3.4). Fapy·dG is less reactive than Fapy·dA, possibly due to resonance
stabilization (Scheme 3.15).
Table 3.4: Half-lives of Fapy·dA/dG.
Fapy·dA Fapy·dG
T [◦C] t1/2 [h] T [◦C] t1/2 [h]
37 103
55 20.5 55 514
72 11.3
91 5.7 90 91
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Also, Burgdorf and Carell performed stability studies on Fapy·dG by in-
vestigating the tetradiisopropyldisiloxane protected derivative (see Figure
3.16).153 For the α-anomer, they found neither anomerization nor deglyco-
sylation within 6 h in DMSO even at 60 ◦C. Furthermore, no decomposition
occurred until the sample was heated to 100 ◦C for 24 h in DMSO and as
expected (see Section 3.3.2.7) the ribose analogue was even more robust.
O
O
O
HN N
NH
O
NHAc
HN
O H
Si
O
Si
Figure 3.16: Disiloxane derivative of Fapy·dG.
In a more polar solvent (H2O/MeCN 1:1), the β-anomer showed slow anomer-
ization at room temperature (Figure 3.17a), but still almost no deglycosy-
lation. The latter was observed to occur slowly at 50 ◦C as seen in Figure
3.17b (H2O/MeOH 1:1, α/β-mixture 1:1). The half-lives were determined to
be t1/2 = 65.2 h for the α- and t1/2 = 37.8 h for β-anomer.
A recent study on EATNs by Hysell and Siegel displayed the dependency of
their stability on the electron deficiency of the nucleobase.63 Various triazine
derivatives were tested, in various solvents and pH. Electron-poor EATNs
were quite stable under physiological conditions whereas electron-rich tri-
azines anomerized, isomerized and deglycosylized quickly in diverse solvents
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and at a broad range of pH. EATNs with intermediate electron density iso-
merized only in protic solvents and were stable at high pH.
(a) Anomerization of Fapy·dG (b) Deglycosylation of Fapy·dG
Figure 3.17: Stability of disiloxane-protected Fapy·dG.
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Figure 3.18: Electron density of investigated EATNs.
Degradation of the β-anomer of 4-amino-6-methoxytriazine EATN, which has
an intermediate electron density, was followed by 1H-NMR of the anomeric
protons at (a) t = 0, (b) t = 1h, (c) t = 9h, (d) t = 30h (D2O, pH = 6.0, Fig-
ure 3.19). One can see that anomerization occurs faster than isomerization
to the pyranose. Nevertheless, the pyranose isomers (P-α, P-β) represent, as
it was already reported for Fapy·dA154 and Fapy·dG,155 the thermodynami-
cally favored products. Furthermore, a small amount of 2-deoxy-D-ribose was
detected, indicating slow cleavage of the glycosidic bond relative to anomer-
ization.
46 CHAPTER 3. State of Knowledge
Figure 3.19: Anomerization, isomerization and deglycosylation of an EATN.
3.4.3 Usability of C-Analogues as Model Compounds
C-Nucleoside is a widely use term, but originally constituted nucleosides con-
taining a C–C glycosidic bond instead of the naturally occurring C–N con-
nection between the sugar moiety and the heterocyclic nucleobase.156 In
nature, a few C-Nucleosides are known (see Figure 3.20).157,158 They often
act as antibiotics and many also exhibit anticancer and/or antiviral activity.
More recently, the term ”C-Nucleoside” was used in an expanded fashion
for several kinds of modifications like expanded C-glycosidic bonds or N→C
substitutions of nucleobase heteroatoms. Some examples are shown in Figure
3.21.159–162
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Figure 3.20: Naturally occurring C-nucleosides.
Another class of modern C-nucleosides are homo-C-nucleosides, which were
first introduced by Gensler et al.163,164 following many others.165–167 Homo-
C-nucleosides feature a methylene bridge between the anomeric carbon atom
of the sugar portion and a carbon in the aglycon (nucleobase).
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Greenberg et al. used a methodology developed by Townsend et al.168 to syn-
thesize homo-C analogues of Fapy·dA and Fapy·dG in order to avoid lability
problems, such as anomerization, isomerization, and deglycosylation (see Sec-
tion 3.4.2).169 He showed computationally by molecular modeling studies and
experimentally by duplex melting studies that the homo-C anologs are good
models for the formamidopyrimidine lesion.65,170
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Figure 3.22: Fapy·dA and its homo-C analog.
Additionally, Berstis showed computationally in her master thesis that the
electron distributions in nucleobases 2-aminopyrimidine (D)1 and 2,4-diamino-
pyrimidine (D-NH2) are quite similar to their natural analogue adenine.66
The calculated electron distributions of the single nucleobases D (nucleobase
of the corresponding homo-C nucleoside), and D-NH2 (nucleobase of the cor-
responding EAN) as well as pairing of those with uracil show clear similarity
to adenine and its pairing to uracil (see Figure 3.23).
1Nomenclature was adopted from Berstis, but is systematically incorrect.
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Figure 3.23: Calculated electron distributions of nucleobases A and D.
Based on the cognition that homo-C nucleosides seem to be good models for
EANs, Lo¨pfe synthesized a homo-C pyranose nucleic acid as a model of the
corresponding pyranose EAN.171 He was able to investigate its base pairing
ability, which is in structural aspects similar to its EAN analogue.
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Figure 3.24: Pyranose EAN and its homo-C analog.
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3.5 Synthesis of Oligonucleotides by the Phos-
phoramidite Approach
The discovery and elucidation of the DNA structure provided the motiva-
tion to find a way to synthesize oligonucletoides of defined sequences.72,81
Michelson and Todd reported the first chemical synthesis of a dinucleotide
in 1955 following the synthetic approach seen in Scheme 3.4.172 Through
the years, many approaches have been developed and modified by introduc-
ing new phosphorylating and condensing reagents but at least one milestone
should be mentioned here. Letsinger et al. have developed the so called
”phosphite triester” methodology (Scheme 3.5).173,174
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Scheme 3.5: ”Phosphite triester” methodology.
The approach that is currently the most commonly used for oligonucleotide
synthesis was evolved by Beaucage et al. and is only a small variation of the
phosphite triester methodology: the phosphoramidite approach.175 Enhance-
ments of this methodology have led to an incredible collection of reagents and
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conditions, which allows fine tuning for countless specific problems. A broad
review article by Beaucage summarizes the progress of the last decades.176
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Scheme 3.6: ”Phosphoramidite methodology”.
Oligonucleotide synthesis by the phosphoramidite approach is a 3’→5’ chain
elongation methodology. The reaction cycle contains four main steps: cou-
pling, capping/oxidation, detritylation and a final cleavage of the support
(Scheme 3.6).
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1. Coupling: In the first step, activated (2-cyanoethyl)phosphoramidite
(CE PA) reacts with a 5’-deprotected nucleotide bound to a solid sup-
port. Standard protocols for automated oligonucleotide synthesis use
typically 1H-tetrazole for activation of CE PA, but, alternatively, other
tetrazole derivatives, like 5-(ethylthio)-1H-tetrazole for instance, can be
used (Scheme 3.7).
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Scheme 3.7: Phosphoramidite activation.
2. Capping: In order to protect uncoupled 5’-OH groups, a mixture of
1-methylimidazole in THF and 2,6-dimethylpyridine in Ac2O is used.
Oxidation: After capping, the solid support bound oligonucleotide is
treated with I2 in THF/pyridine/H2O to oxidize the phosphite (Scheme
3.8).
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Scheme 3.8: Phosphite oxidation.
3. Detritylation: In the last step of the cycle, the protection group (DMT)
at the 5’-position is cleaved with trichloroacetic acid in CH2Cl2 to make
the 5’-end available for the next coupling cycle.
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4. Clevage: After finishing the synthesis, the oligonucleotide needs to be
released from the support and fully deprotected. This is accomplished
with conc. aq. NH3-solution, which cleaves off all protection groups on
the nucleobases and phosphates and additionally releases the linker to
the solid support (Scheme 3.9).
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Scheme 3.9: Final cleavage.
Chapter 4
Own Work
4.1 Synthesis towards EAN
EANs can undergo anomerisation, furanose-pyranose isomerisation and cleav-
age of the glycosidic bond as known from work of Hysell,63 Greenberg64 and
Cadet154,155 (see section 3.4.2). In order to investigate the inertness of our
two target exocyclic amino nucleosides D and E, we attempted to synthesize
them following a strategy developed by Greenberg (Scheme 4.1).169
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Scheme 4.1: Retrosynthetic analysis.
Greenberg developed this strategy for the synthesis of Fapy·dG, a DNA le-
sion caused by oxidative stress as seen in section 3.4. Fapy·dG contains an
electron-poor pyrimidine and therefore differs significantly from our system.
The key step of this synthesis is the final nucleophilic attack of a free amino
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group at the chlorinated pyrimidine (Scheme 4.2), a reaction which seems
to work only with electron-poor aromatic rings. The coupling failed in our
hands under various conditions. Consequently Greenberg’s methodology is
not generally applicable. These synthetic problems and the expectation of
an labile product persuaded us to develop a model system which is synthet-
ically available, thermodynamically stable, and sterically and electronically
comparable.
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Scheme 4.2: Unsuccessful coupling.
4.2 Development of a Model System
Based on Greenberg’s and Berstis’s results, which showed carbon analogues
to be useful models for EANs,66,169 we decided to follow this approach.
Homo-C nucleosides were not expected to be susceptible to either anomerisa-
tion/isomerisation or deglycosylation. They should be sterically quite similar,
not dramatically different electronically, and therefore good models for the
purpose of investigating configurationally stable analogs of EANs in oligonu-
cleotides.
A model system based on a four letter code would therefore consist of the two
natural deoxynucleosides dC and dU and, in addition, two artificial homo-C
deoxynucleosides dD and dE (Scheme 4.1). This system allows for the study
of base pairing abilities with stable species in the absence of an anomerisation
and isomerisation equilibrium.
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Figure 4.2: Model system with homo-C deoxynucleosides dD and dE.
4.3 Retrosynthetic Analysis
Greenberg et al. applied homo-C nucleosides by forming the glycosidic bond
with preconstructed pyrimidine derivatives via a Wittig-type reaction, a method
first introduced by Townsend et al. (Scheme 4.3).168
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Scheme 4.3: Wittig reaction.
Due to the fact that a Wittig reaction is not compatible with an amino func-
tion, we decided to use another strategy and build up the pyrimidine ring by
condensation. Nucleoside dD (1) was prepared from enaminoketone 2, which
acts as an equivalent of a β-ketoaldehyde, by condensation with guanidine
(Scheme 4.4). Unfortunately nucleoside dE (7) can not be accessed in the
same way, due to the poor nucleophilicity of urea, but 1 can be transformed
to 7 via a diazonium ion (Scheme 4.5). Enaminoketone 2 can be synthesized
with Bredereck’s reagent177 from ketone 3, which is in turn available from
acetal 4, a simply reachable derivative of 2-deoxy-D-ribose (6). Because the
synthetic results showed the methods used were not diastereoselective, the
synthesis was carried out as an anomeric mixture. Separation of α- and
β-anomers was achieved by HPLC at the final stage.
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Scheme 4.5: Retrosynthetic analysis dE (7).
4.4 Synthesis of dD and its CE PA
Nucleoside dD (1) was synthesized in seven steps from 2-deoxy-D-ribose (6)
(Scheme 4.6).
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(a) i) MeOH, HCl, rt, 15min; ii) Ag2CO3. (b) i) NaH, THF, 0°C, ; ii) INBu4, BnBr, rt, 4h. (c) SnCl4, 9, MeCN, 0°C,
1h. (d) Zn(OAc)2, NaOMe, MeOH, rt, 24h. (e) 
tBuOCH(NMe2)2, Tol, 70°C, 20h. (f) i) EtOH, NaOEt, 75°C, 5h; ii) 
(CH5N3)2*H2SO4, 40°C to 70°C, 15h. (g) BBr3, DCM, 0°C, 3min.
f
0.2g, 73%
O
HO
OH
N
N
NH2
dD (1)
d
Scheme 4.6: Synthesis of dD (1).
According to the literature178 6 has been converted to acetal 5 almost quan-
titatively. Benzyl protection of the free hydroxy groups179 gave 8 as an
anomeric mixture of α/β ∼1.2:1, which was separable by column chromatog-
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raphy, but was used as a mixture for further synthesis. Coupling of 8 with
trimethyl(prop-1-en-2-yloxy)silane (trimethylsilylenolether of acetone, 9) in
the presence of SnCl4 formed the homo-C glycosidic bond (Scheme 4.7).180–182
C(1) of the introduced propan-2-one unit represents essentially the methylene
bridge of the later homo-C nucleoside.
O OMe
RO
OR
O
RO
OR
O
SnCl4, MeCN
R = Bn: 8
    = Bz: 14
OSiMe3
R = Bn: 10
    = Bz: 15
Scheme 4.7: SnCl4 coupling.
This coupling worked in excellent yields if freshly distilled SnCl4 was used.
Unfortunately a separation of the anomers by column chromatography was
not successful and determination of diastereomers and their ratios was per-
formed by peak assignment with COSY and NOESY experiments and peak
integration in 1H-NMR (Figures 4.3, 4.4).
O
OBn
BnO
C
1
H
O
H
10
3'
5'
4'
(a) Analyzed protons at C(1) (b) 1H-NMR of H2C(1) in ketone 10
Figure 4.3: Determination of the anomeric ratio of ketone 10 by 1H-NMR.
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Figure 4.4: NOESY-NMR of ketone 10.
The diastereoselectivity of this coupling reaction was found to be strongly
dependent on the educt’s configuration at C(1). If 8α was used, 10 was ob-
tained in a ratio α/β 5:1, but reaction with 8β resulted in a ratio 10α/10β
2.7:1. The same reactions were also carried out with benzoyl-protected ac-
etal 14, but the best result obtained was 15α/15β 2:1. These results were
unsatisfying since the α anomer is of marginal interest for this project. A
Zn(II)-mediated epimerization developed by Shao et al. led us to an accept-
able result.183 Treating diverse anomeric mixtures of 10 with Zn(OAc)2 under
basic conditions shifted the ratio to a two-fold excess of β-anomer. Shao et al.
hypothetized this epimerization to be initiated by the formation of Zn-enolate
and it is known that Zn-enolates adopt only the Z-configuration,184 which can
be stabilized by intramolecular chelation to the furanose ring oxygen. This
coordination weakens the C(1’)–O bond and leads to a retro Michael reaction.
Subsequent hetero-intramolecular Michael addition results in the formation
of the β-homo-C glycoside (see Scheme 4.8).
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Scheme 4.8: Epimerization of 10.
In the next step of the synthesis, Bredereck’s reagent was used to achieve
enaminoketone 11. Experiments performed by Lo¨pfe62 have shown Bred-
ereck’s reagent to be an effective derivative of DMF to access enaminoketone
11, although a variety of formamide acetals are known to act similar.185 Bred-
ereck’s reagent (tert-butoxybis(dimethylamino)methane, 16) was synthesized
from DMF as reported in the literature (see Scheme 4.9).177,181
H N
O
H N
O
H N
N
t-BuO N
N
a
10.0g
(a) i) Me2SO4, rt, 0.5h; ii) 60°C, 3h. (b) C6H6, NH(CH3)2, 80°C, 1h. (c) KO
tBu, rt, 1.5h.
b
80% (over 2 steps)
c
23.2g, 59%
SO4Me SO4Me
16
Scheme 4.9: Synthesis of Bredereck’s reagent (16).
Compound 10 was converted with Bredereck’s reagent (16) to enaminoketone
11, which was not isolated, but treated with guanidinium sulfate under basic
conditions in EtOH at 70 ◦C for 4 h, under which conditions a condensation
to aminopyrimidine 12 takes place. A proposed mechanism for this reaction
is shown in Scheme 4.10.
Unexpectedly, a mixture of isomers 12α/β and 13α/β was obtained in this
reaction, which can be explained by an addition of Bredereck’s reagent at
the undesired position C(1) instead of C(3) (see Scheme 4.11). Under these
reaction conditions a product ratio 12/13 1:2 was observed. By screening
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Scheme 4.10: Mechanism of guanidinium condensation.
various reaction conditions, we have been able to shift this ratio toward the
desired product (see Table 4.1). Heating the enaminoketone intermediate
under basic conditions before adding guanidinium sulfate gave 12 as the main
product, a fact that indicates an isomerisation taking place from 17α/β to
11α/β (see Scheme 4.12). This reaction needs to be controlled very carefully
because a preheating of the enaminoketone under basic conditions over 60 ◦C
leads to partial decomposition.
O
BnO
OBn
O
O
BnO
OBn
O
NMe2
O
BnO
OBn
O
NMe2
O
BnO
OBn
N
N
NH2
O
BnO
OBn
N
N
NH2
16
10!/"
13!/"12!/"
(CH5N3)2*H2SO4
11!/" 17!/"
Scheme 4.11: Condensation to 12 and 13.
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Table 4.1: Tested reaction conditions for the pyrimidine condensation.
Reaction conditions Ratio 12/13 Yield [%]
EtOH, NaOEt, (CH5N3)2∗H2SO4, 70◦C, 4h 1:2 73
i) EtOH, NaOEt, (CH5N3)2∗H2SO4, 40◦C, 1.5h
ii) EtOH, NaOEt, (CH5N3)2∗H2SO4, 70◦C, 24h 1:1 56
i) EtOH, NaOEt, 60◦C, 4h
ii) EtOH, NaOEt, (CH5N3)2∗H2SO4, 70◦C, 18h 6:1 58
i) EtOH, NaOEt, 70◦C, 5h
ii) EtOH, NaOEt, (CH5N3)2∗H2SO4, 70◦C, 15h 85:1 13
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Scheme 4.12: Proposed isomerisation.
Isolation of the four isomers 12α/β and 13α/β by column chromatography
was not successful and necessitated a separation by HPLC, which turned out
to be difficult as well. Finally, the separation was performed with a prepar-
ative Spherisorb R©-NH2 column and Hex/MeOH/EtOH 97:2:1 as eluant.
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In Figure 4.5, one can see the chromatograms of two different isomeric mix-
tures. The upper chromatogram shows a mixture of 12α/12β/13α/13β
1.7:1:1.9:3.3 resulting from a synthesis without an anomerisation step of ke-
tone 10 and with unmodified guanidinium condensation1. The lower chro-
matogram displays a mixture of isomers obtained from an improved synthesis
giving 12β as the main product and 12α, 13α and 13β in 30.0 %, 2.8 % and
9.2 % of the yield, respectively.
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Figure 4.5: HPLC chromatograms of mixtures of 12α/β and 13α/β.
1Chromatogram is shifted up by 40 mAU for better clarity.
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Identification of the isomers was achieved by NMR experiments. Figures 4.6
and 4.7 show the 1H-NMR of 12β and the assignment of its peaks which
was confirmed by DQF-COSY-, NOESY-, and HSQC-NMR. A sector of the
NOESY spectra of 12β is displayed in Figure 4.8, where one can see a NOE
correlation between HC(1’) and HC(4’) but not between HC(1’) and HC(3’).
The reversed correlations can be found in 12α as well as in 13α, whose
NOESY-NMR is shown in Figure 4.9. An additional proof that our classi-
fications of the different isomers is correct is given by the X-ray structure
we obtained from 13α, unfortunately, the only isomer we have been able to
crystallize (see Figure 4.10).
Figure 4.6: 1H-NMR of 12β.
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(a) Aromatic region
(b) Benzylic protons, HC(1’), HC(3’), HC(4’) and H2C(5’)
(c) Protons of methylene bridge and H2C(2’)
Figure 4.7: Detailed sections of 1H-NMR of 12β.
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Figure 4.8: NOESY-NMR of 12β.
Figure 4.9: NOESY-NMR of 13α.
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Figure 4.10: Solid state conformation of 13α.
Figure 4.11: Packing of 13α.
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In the solid state, 13α is found as a single conformer in which the sugar occurs
in a C2
′
-endo and the glycosidic bond in anti conformation. The torsion
angle χ (O5–C1–C6–C7) is 153.9 ◦ (antiperiplanar). The three-dimensional
structure is stabilized by hydrogen bonds; each aminopyrimidine ring forms
four hydrogen bonds to two other nucleobases (see Figure 4.11).
From the NMR experiments of nucleoside 12β and the observed coupling
constants on can deduce rudimental information about its structure. The
sugar pucker exists presumably in the C2
′
-endo conformation, because a high
3J coupling constant of 10.2 Hz was found between HβC(2’) and HαC(1’).
This indicates roughly a Hβ–C(2’)–C(1’)–Hα torsion angle of about 150◦,
which is only possible in the C2
′
-endo conformation.104 Between HαC(2’) and
HαC(1’) a 3J coupling constant of 5.2 Hz was found. The corresponding values
observed for 2’-deoxyadenosine were 8.0 Hz (HβC(2’) – HαC(1’)) and 6.0 Hz
(HαC(2’) – HαC(1’)).186 Additionally, one can assume that the torsion of
the glycosidic bond is in the anti conformation, because no NOE correlations
were found between the aromatic protons and HC(3’) or H2C(5’).
Concerning the structural data, we can assume our nucleoside dD to be quite
similar to its analog 2’-deoxyadenosine. Even though nucleoside dD is more
flexible than dA, it is present in the anti conformation and should fulfill the
fundamental structural requirements to be a possible analog of dA.
After successful separation and identification of our desired homo-C nucleo-
side 12β, we carried on the synthesis by deprotection of the hydroxy groups
giving dD (1). Thereafter, the fully unprotected nucleoside needed to be
transformed to its cyanoethyl phosphoramidite (dD CE PA, 20), which has
been done by well-established chemistry in satisfying yields as seen in Scheme
4.13.187 After selective monobenzoyl protection of the amino function, the
5’-hydroxy group was coupled with dimethoxytrityl (DMT), following a pro-
cedure described by Eschenmoser et al.48 In a final step, the 3’-hydroxy group
was converted to a cyanoethyl-N,N-diisopropyl phosphoramidite, namely dD
CE PA (20).
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(a) i) TMSCl, Pyr, 0°C, 12h; ii) BzCl, rt, 12h. (b) DMTCl, (Bu4N)ClO4,
Pyr, rt, 16h. (c) PCl(N(i-Pr)2)(OEtCN), NEt(i-Pr)2, rt, 2h.
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Scheme 4.13: Synthesis of dD CE PA (20).
4.5 Attempted synthesis of dE
A second target molecule of this project was the G-analogue homo-C nucle-
oside dE (7). Following the original idea, which was outlined in Scheme 4.5,
7 should be synthesized from homo-C nucleoside dD (1). Because simple
hydrolysis of the 2-aminopyrimidine under basic conditions was not success-
ful, we decided to try another synthetic route. Due to the intricate sep-
aration of homo-C nucleoside 12β, we tested this methodology with the
undesired product C–nucleoside 13α/β. The latter was first converted to
its 2-iodopyrimidine analogue 22, following a procedure by Loren188 as seen
in Scheme 4.14. A nucleophilic aromatic substitution with NaOBn led to
compound 23,189 which was then fully deprotected in one step, giving the
pyrimidone C nucleoside 24. This trial showed that pyrimidones could be
accessed by this methodology, but the first step, a radical iodization, worked
only in poor yields. A proposed mechanism for this reaction is shown in
Scheme 4.15.
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(a) 10M NaOH, H2O, 90°C, 2d. (b) (C5H11)ONO, CH2I2, CuI, THF, 60°C, 
1.5h. (c) NaOH, BnOH, MeCN, 85°C, 3.5h. (d) BBr3, DCM, 0°C, 3min.
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Scheme 4.14: Attempted synthesis of dE.
N N
NH2
R
N N
N
R
N
H H
O
O
N
O
N N
N
R
N
H
OH
N N
N
R
N
O
N N
N
R
N
OR
N N
R
I
H
I
H
N N
R
I
Scheme 4.15: Proposed mechanism.
Various reaction conditions have been tested to improve the iodination of the
2-aminopyrimidine, but unfortunately yields up to only 20% were achieved
(Table 4.2).190–194 These results convinced us to work out a better strategy
that allows us to access homo-C nucleoside dE easier and in larger scale.
4.5. Attempted synthesis of dE 71
Table 4.2: Tested conditions for iodination of 2-aminopyrimidine 13.
Reaction conditions Yield [%]
(C5H11)ONO, Benzene, I2, 80◦C, 36h –
(C5H11)ONO, CH2I2, 85◦C, 3.5h 11
(C5H11)ONO, CH2I2, CuI, I2, THF, 66◦C, 0.5h 18
(C5H11)ONO, CH2I2, CuI, THF, 60◦C, 1.5h 19
CH2I2, CuI, THF, 66◦C, 1.5h 14–20
Scheme 4.16 outlines two possible alternative strategies, which have been
tried to synthesize homo-C nucleoside dE. The upper one targets toward
a Wittig-type reaction to build up the homo-C glycosidic bond, a method
which has been developed and used by Townsend.168 The key intermedi-
ate of this method would be a Wittig reagent of the suitable substituted 4-
methylpyrimidine.195 Unfortunately, we have not been able to synthesize such
a compound, although we tried several different pathways and derivatives.
The classical approach via a 4-(bromomethyl)pyrimidine failed with various
substitution patterns as well as under a series of conditions because bromi-
nation of the corresponding 4-methylpyrimidine always yielded 5-bromo-4-
methylpyrimidine. Also, a second approach, starting with the N-oxide of a
4-methylpyrimidine,196–199 which could be used in a Bo¨ckelheide reaction to
further functionalize the methyl group, failed in our hands.
A more promising strategy is shown at the bottom of Scheme 4.16. The
fundamental idea is to build up the glycosidic bond by a nucleophilic at-
tack of a double lithiated 4-methylpyrimidone to the lactone of deoxyri-
bose.200 As seen in Scheme 4.17, lactone 26 was synthesized with two dif-
ferent silyl protecting groups, TBDMS (26a) and bridging tetraisopropyl-
disiloxandiyl(26b),162,201,202 according to the literature and was, thereafter,
coupled with double-lithiated 2-hydroxy-4-methyl-pyrimidine 27.203 Instead
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of desired product 28, which should be converted to homo-C nucleoside 29,
compound 30 was formed in reactions under various conditions and with both
silyl protecting groups. 30 can be explained by a sugar ring opening during
nucleophilic attack, resulting in a enol that is stabilized by conjugation with
the pyrimidin-2(1H)-one (see Scheme 4.18).
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(a) Br2, H2O, 0°C, 20h. (b) RCl, DMF, rt, 20h.
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Scheme 4.17: Attempted synthesis of dE.
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Scheme 4.18: Sugar ring opening.
These results were disappointing because such ring opening in similar reac-
tions is, to the best of our knowledge, not described in the literature, but
the methodology seems to be promising and would allow to access homo-C
nucleoside dE in only four steps. Ring opening could possibly be avoided by
insertion of a good leaving group at C(1), such as the C(1)–Cl compound.204
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4.6 Base Pairing Studies
In order to investigate the potential of our artificial nucleotide dD to mimic
the natural nucleobase dA, we incorporated it into oligonucleotides and to
perform base-pairing studies. We decided to use a system that was devel-
oped and investigated, in another contex, by Breslauer. He used a non-self-
complementary 13mer oligonucleotide (see Figure 4.12) to study the thermo-
dynamic contribution that DNA single-stranded order makes to DNA duplex
formation.205–207
5’– C G C A U G A G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C U C A U G C G –5’
Figure 4.12: Investigated complementary oligonucleotides.
5’– C G C A U G X G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C Y C A U G C G –5’
Figure 4.13: Positions to modify in the complementary strands.
4.6.1 Synthetic Constructs – 13-mers
We planned to synthesize the two complementary strands and to modify
the highlighted middle positions X and Y. dA, dG, dC, dU, and dD should
be incorporated at these positions in both strands. Accordingly, we had to
synthesize ten different strands, five of each kind. To simplify matters, we
will call the two different kinds of strands ”A” and ”B” and number them
according to Table 4.3.
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Our intention was to combine the complementary strands in all 25 possible
combinations and perform melting experiments with these double-stranded
oligonucleotides in order to obtain a complete set of thermodynamic data and
to determine the base-pairing abilities of homo-C nucleoside dD compared to
all other bases.
Table 4.3: Abbreviations for the synthesized strands.
Kind of strand Oligonucleotide Abbreviation
Strand A 5’–CGCAUGAGUACGC–3’ A1
5’–CGCAUGDGUACGC–3’ A2
5’–CGCAUGGGUACGC–3’ A3
5’–CGCAUGUGUACGC–3’ A4
5’–CGCAUGCGUACGC–3’ A5
Strand B 5’–GCGUACACAUGCG–3’ B1
5’–GCGUACDCAUGCG–3’ B2
5’–GCGUACGCAUGCG–3’ B3
5’–GCGUACUCAUGCG–3’ B4
5’–GCGUACCCAUGCG–3’ B5
Oligonucleotides were synthesized on an automated DNA synthesizer using
the Phosphoramidite approach and purified as explained in details in Sections
3.5 and 6.20. Figure 4.14 shows the purification of crude oligonucleotide B2
by HPLC. Due to incomplete couplings, oligonucleotides of reduced length are
present in the raw product as seen in the upper chromatogram.2 The lower
chromatogram exhibits the same oligomer after separation on an analytical
DEAE-ion exchange HPLC column.
2Chromatogram shifted up by 1 mAU for better clarity
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Figure 4.14: Purification of crude oligonucleotide B2 by HPLC.
4.6.2 Melting Studies
After purification, the oligonucleotides were used to measure melting curves
of double-stranded DNA by temperature-dependent UV-spectroscopy. Com-
plementary sequences were combined in a 1:1 ratio in buffer solution and
slowly heated up recording the absorbance at 260 nm as a function of tem-
perature. The principle of such an experiment was developed by Thomas208
more than 50 years ago and is based on hypochromicity – an effect which is
observed in oligonucleotides as well as in other (bio-)polymers.209 Double-
stranded DNA with a well defined three dimensional structure absorbs less
light than single-stranded DNA. Accordingly, melting of DNA, the change
from an associated duplex at low temperature to unfolded single strands at
high temperature, can be followed by an increase of UV absorbance (see Fig-
ure 4.15a). Duplex denaturation of DNA leads to a hyperchromism of 15
% – 20 %.210 In principle, such a thermal denaturation curve could also be
obtained with fluorescence emission spectroscopy,211 NMR measurements,212
circular dichroism,213 or Raman spectroscopy.214
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(a) Exemplary melting curve (b) Determination of Tm
Figure 4.15: Melting curves and determination of Tm.210
From temperature dependent melting curves one can determine the melt-
ing temperature (Tm) of a given double-stranded DNA (see Figure 4.15b).
Its Tm corresponds to the temperature at which half of the sample is folded
(double-stranded), and half is unfolded (single-stranded). Several parameters
influence the strength of duplex binding and therefore the melting tempera-
ture Tm.210 First, the length of the oligonucleotide affects the Tm. Second,
the composition of the complementary oligonucleotides makes a difference in
Tm, which increases linear with the molar content of G-C base pairs. Third, in
some cases Tm is dependent on the oligonucleotide concentration. In the case
of an intramolecular complex (e.g. i-Motif), the Tm should be concentration
independent, whereas in the case of bimolecular (autocomplementary or two
different complementary oligonucleotides) or multimolecular complexes Tm
should be dependent on the concentration. Additionally, other parameters
like, ionic strength, the nature of the salt, or the pH influence the melting
temperature. An increase in ionic strength leads to an increase of the Tm,
because the cation concentration will partially neutralize the net charge of
the nucleic acid, which is a negatively charged polyelectrolyte (see section
3.3.2.5).215 Moreover, pH plays an important role in the lability of DNA in
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consideration of the protonation of nucleobases.
From a measured melting curve one can now deduce the thermodynamic pa-
rameters of the melting process and therefore quantify the strength of duplex
binding. Several different methods to calculate the thermodynamic data are
common and will be explained in details later in this section.
A melting experiment needs to be set up carefully. For instance, buffer so-
lutions and samples should be degassed in order to avoid air bubbles, and
parameters of the measurement should be examined precisely. The heating
temperature gradient is a crucial point. A temperature slope that is too
steep would lead to an inaccurate result, because the thermal equilibrium
between double- and single-stranded DNA is not reached. Figure 4.16 shows
a typical melting curve, recorded with a temperature gradient of 12 ◦C per
hour. A reverse temperature (RT) scan does not differ significantly, but a 24
◦C/h scan is shifted considerably. This observation indicates that 12 ◦C is an
adequate gradient, which allows the sample to reach its thermal equilibrium
but, on the contrary, heating the sample by 24 ◦C/h is too fast and results
in a wrong melting temperature (Tm).210
Melting curves were measured for four different oligonucleotide concentra-
tions in each case as seen in Figure 4.17. Because Tm is concentration-
dependent in the case of a bimolecular association of two independent non-
self-complementary strands, at least three measurements are necessary to
calculate the thermodynamic parameters ∆G◦, ∆H◦ and ∆S◦. The interpre-
tation of the achieved data and calculations of the thermodynamic parame-
ters were performed in two different ways in order to verify the results. First,
melting curves were analyzed graphically in an absorbance vs. temperaure
plot to determine the melting temperatures (see Figure 4.15a). Furthermore,
a fraction folded plot was converted from the absorbance vs. temperature plot
to approve this values. A fraction folded plot is a representation of fraction
folded (θ) vs. temperature. The lower baseline in the Absorbance vs. Temp.
plot corresponds to the associated, double stranded duplex (θ = 1, T) Tm),
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Figure 4.16: Testing for an adequate temperature slope.
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
43 48 53 58 63 68 73 78 83
Temperature [°C]
F
r
a
c
ti
o
n
 f
o
ld
e
d
9.73 µM
6.08 µM
3.80 µM
2.38 µM
Figure 4.17: Example of a fraction folded plot with four different oligonu-
cleotide concentrations.
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whereas the upper baseline corresponds to the dissociated, single stranded
oligonucleotides (θ = 0, T * Tm). Accordingly, the melting temperature
T = Tm corresponds to θ = 0.5. A fraction folded plot is derived by the
Formula 4.1, whereat L0T and L1T correspond to the baseline absorbance
values of the unfolded and folded species, and AT is the absorbance at the
given temperature.
θT =
L0T − AT
L0T − L1T (4.1)
With the obtained Tm values, one can now calculate the Van’t Hoff pairing
standard ethalpies ∆H◦ and standard entropies ∆S◦ according to described
methods.216,217 By plotting 1/Tm as a function of the initial oligonucleotide
concentration (CTotal), one may then write:
1
Tm
=
∆S◦
∆H◦
+
R ∗ ln(CTotal/2)
∆H◦
(4.2)
3.06E-03
3.07E-03
3.08E-03
3.09E-03
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3.11E-03
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1
/T
m
Figure 4.18: Plot of 1/Tm vs. ln CTotal.
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Out of this correlation, one can deduce ∆H◦ and ∆S◦ as explained in Figure
4.18 and Formulas 4.4, 4.5. Finally, one can calculate the Gibbs free enthalpy,
which, by definition, may be written as:
∆G◦ = ∆H◦ − T ∗∆S◦ (4.3)
slope = R/∆H◦ (4.4)
intercept =
∆S◦ −Rln4
∆H◦
(4.5)
These parameters can also be determined from a second plot: the Van’t Hoff
representation, a correlation of ln Ka vs. 1/T (see Figure 4.19 and Formulas
4.7, 4.8). Ka, the affinity constant, can be calculated from the fraction folded
θT according to Formula 4.6, where C0 is the single-strand concentration and
one should generally restrict the analysis to the temperature range for which
0.15 < θ < 0.85.210
Ka =
θT
C0 ∗ (1− θT )2 (4.6)
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 (
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Figure 4.19: Van’t Hoff plot: ln Ka vs. 1/T.
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slope = −∆H
◦
R
(4.7)
intercept =
∆S◦
R
(4.8)
Both discussed representations to determine the thermodynamic parameters
require ∆H and ∆S to be temperature-independent, an assumption that is
not always valid but as described by Chaires very difficult to analyze.218
The resulting thermodynamic parameters should be equal for both calcula-
tions and can be compared. Problems can occur if the baselines are not set
exactly, for instance. Such a misinterpretation has a decisive effect on the
outcome of the 1/Tm vs. ln CTotal calculation, but can be perceived because it
induces a significant curvature of the Van’t Hoff plot.
On the following page, all accumulated thermodynamic data are summarized.
I will integrate this comprehensive set of data and draw conclusions that are
valid for this special case of double-stranded DNA as well as characterize the
new artificial nucleotide dD in general.
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Table 4.4: Summary of ∆G◦ values [kcal/mol].
Strand A
A D G U C
St
ra
nd
B
A -14.9 -12.7 -14.2 -18.1 -13.6
D -13.9 -11.8 -14.2 -15.2 -12.8
G -12.6 -11.4 -13.8 -15.5 -17.5
U -18.5 -12.6 -16.0 -14.6 -14.0
C -13.0 -11.4 -18.2 -13.5 -13.2
Table 4.5: Summary of ∆H◦ values [kcal/mol].
Strand A
A D G U C
St
ra
nd
B
A -76.8 -57.0 -64.9 -88.6 -70.8
D -76.8 -56.1 -77.1 -80.9 -70.3
G -57.5 -54.2 -67.6 -84.1 -79.4
U -94.7 -54.3 -87.9 -77.9 -78.5
C -62.7 -48.3 -86.3 -70.5 -76.8
Table 4.6: Summary of ∆S◦ values [cal/mol∗K].
Strand A
A D G U C
St
ra
nd
B
A -208 -148 -170 -237 -192
D -211 -149 -211 -220 -193
G -151 -144 -181 -230 -208
U -256 -140 -241 -212 -216
C -167 -124 -229 -191 -213
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Table 4.7: Comparison of dA and dD by ∆∆G◦ values [kcal/mol].
Strand A Strand B
A D ∆∆G◦ A D ∆∆G◦
S
tr
an
d
B
A -14.9 -12.7 2.2
S
tr
an
d
A
A -14.9 -13.9 1.0
D -13.9 -11.8 2.1 D -12.7 -11.8 0.9
G -12.6 -11.4 1.2 G -14.2 -14.2 0.0
U -18.5 -12.6 5.9 U -18.1 -15.2 2.9
C -13.0 -11.4 1.6 C -13.6 -12.8 0.8
Table 4.8: Comparison of dA and dD by ∆∆H◦ values [kcal/mol].
Strand A Strand B
A D ∆∆H◦ A D ∆∆H◦
S
tr
an
d
B
A -76.8 -57.0 19.8
S
tr
an
d
A
A -76.8 -76.8 0.0
D -76.8 -56.1 20.7 D -57.0 -56.1 0.9
G -57.5 -54.2 3.3 G -64.9 -77.1 -12.2
U -94.7 -54.3 40.4 U -88.6 -80.9 7.7
C -62.7 -48.3 14.4 C -70.8 -70.3 0.5
Table 4.9: Comparison of dA and dD by ∆∆S◦ values [cal/mol∗K].
Strand A Strand B
A D ∆∆S◦ A D ∆∆S◦
S
tr
an
d
B
A -208 -148 60
S
tr
an
d
A
A -208 -211 -3
D -211 -149 62 D -148 -149 -1
G -151 -144 7 G -170 -211 -41
U -256 -140 116 U -237 -220 17
C -167 -124 43 C -192 -193 -1
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4.6.3 Trends in ∆G◦ of pairing
As expected, we have found the highest binding energies in the cases of the
natural Watson-Crick base pairs, A:U and G:C, where we observed ∆G◦,
∆H◦, and ∆S◦ values of -17.5 – -18.5 kcal/mol, -79.4 – -94.7 kcal/mol and -208
– -256 cal/mol∗K, respectively. These values are comparable to the results
measured by Breslauer with the similar 13-mer containing A:T instead of
A:U base pairs.219 He observed ∆G◦ = 20.0 kcal/mol, ∆H◦ = 117.0 kcal/mol, and
∆S◦ = 325.4 cal/mol∗K in 10 mM sodium phosphate buffer solution3.
5’– C G C A T G A G T A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G T A C T C A T G C G –5’
Figure 4.20: 13-mer duplex investigated by Breslauer.
Several properties of the particular single strands and of the double stranded
DNA effect these results and are responsible for the occasionally observed
differences. Simplified, ∆G◦ is in general the sum of the binding between
the two strands (∆H◦, strongly negative: highly favorable) and the stacking
of the strands (∆S◦, very negative: very unfavorable). As one can imagine,
these two parameters are not independent from each other, but influence one
another. The event of duplex formation from two complementary ”random
coil” single strands can be abstractly divided into two parts. First, every
single strand forms a pre-ordered, stacked structure. Then, the pre-stacked
single strands bind to each other and form the duplex. Breslauer has ob-
served that the two complementary single strands already posses > 40% of
the total enthalpy.219 Certainly, duplex formation cannot be considered as an
explicit three-state process, but for better clarity, this is a descriptive model.
Obviously, an optimal prestacking facilitates an effective binding, whereas a
disrupted prestacking disturbs the binding affinity. This interrelation makes
310 mM sodium phosphate, 1 mM EDTA, 1.0 M NaCl, adjusted to pH 7.
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it difficult to draw accurate conclusions about the binding properties of a
single base pair because its influence is spread out over the whole duplex
structure. However, general trends can be identified and will be outlined in
the following discussion.
By comparing the thermodynamic data of dA versus dD against all other nat-
ural nucleobases, a general trend was observed. Binding, as well as prestack-
ing, seems to be weaker in oligonucleotides containing dD compared to those
containing dA. This observation is not surprising due to the fact that the
glycosidic methylene bridge in homo-C nucleosides introduces an additional
degree of freedom into the sugar–nucleobase junction (see Figure 4.21).
O
RO
OR
N
N
NH2
Figure 4.21: Additional degree of freedom in nucleoside dD.
The extra flexibility presumably disrupts the base stacking and weakens the
ability of binding to its counterpart. Furthermore, the aminopyrimidine ring
of nucleoside dD is probably less polarizable than its purine analogue dA and,
therefore, less compatible for binding and stacking. Pyrimidines generally
stack less strongly than purines, presumably because purines have larger
surface area and greater polarizability.115
We observed a slight selectivity of dD to bind to its target complementary
base dU. Unfortunately, binding to the nucleobase dA was also found to be
in the same range of strength as, in one case, to nucleoside dG (see Figure
4.22). If nucleoside dD in strand A (A2) is merged with all complementary
stands B, the combinations D:A (A2B1) and D:U (A2B4) expose the highest
affinities of about ∆G◦ ≈ 12.6 kcal/mol. Although the values are lower than in
the dA series (A1, ∆G◦ ≈ 15 kcal/mol), a clear similarity can be noticed.
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Figure 4.22: -∆G◦ values [kcal/mol] of the dA and dD series.
This decrease in binding affinity to their complementary bases may be ex-
plained by the different stacking abilities of dA and dD. In strand A, the
middle position is flanked by two guanosines. As known in the literature, dA
and dG have the highest stacking free energies of the four natural nucleosides
and can therefore form stable stacked structures when they occur in a row
as in strand A1 (see section 3.3.2.5).115 On the other hand, the stacking is
disrupted if nucleoside dD occurs in the middle position, as in strand A2,
and the binding affinity decreases. ∆G◦ values of strand A1 against all other
complementary strands were in the range of -12.6 – -18.5 kcal/mol, whereas the
valus of strand A2 were in the range of -11.4 – -12.7 kcal/mol. In general, all
melting studies with A1 and A3, oligonucleotides with three purines in a row
located in the middle, showed highly negative ∆S◦ values and support this
argument.
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The fact that dD forms somewhat stable duplexes with dU, as well as with
dA, allows the assumption that hydrogen bond motifs between these nucle-
obases as outlined in Figure 4.23 are present. The structural changes needed
to arrange the proposed bonding between dD and dA, for instance, possibly
does not dramatically disturb the stacking.
If we compare the strands B1 and B2, which accommodate dA and dD in
the middle positions, respectively, the trend, that the highest ∆G◦ values
are found if dD pairs with dU and dA, is also observed. In contrast to the
A2 series, quite high ∆S◦ values are found in the B2 series, which indicate a
quite stable stacking of dD with its flanking cytidine nucleobases in strand
B. C is known to induce strong dipoles in its nearest neighborhood and may
fix the flexible homo-C nucleotide dD in a stable, stacked conformation.
In general, all observed thermodynamic data demonstrate that dD is much
more similar to dA in strand B than in strand A. ∆∆G◦, ∆∆H◦, and ∆∆S◦
are much smaller when we compare dD and dA in strand B than the corre-
sponding data of strand A. The flanking cytidines seem to be able to influence
nucleotide dD in a manner that allows it to stack and pair quite analogous to
dA. Such an amplitude of a nearest neighborhood effect was absolutely not
expected and the question of how other flanking nucleotides would influence
the binding affinity of homo-C nucleotide dD arises. Unfortunately, we will
not be able to answer this problem in this thesis.
A strong binding was also found in this series in the case where dD pairs
with dG (B2A3, ∆G◦ = 14.2 kcal/mol). On one hand, the already mentioned
stacking effect of three purines in a row in strand A3 could be responsible for
the high ∆S◦ value. But, on the other hand, a possible hydrogen bond motif,
as seen in Figure 4.23, can also be proposed based on the observed high ∆H◦
value.
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Another exceptional effect we have observed, was a strong affinity of strands
were dG is in line with dU (A3B4 and A4B3, ∆G◦ ≈ 16 kcal/mol). Since a
hydrogen bond motif can be excluded, stacking forces presumably are respon-
sible for this affinity.
N
N
HN H
N
N
HN
N
N
O
O
H
N
N
H2N
O dG
dU
N
NH
H
N
N
N
N
NH
N
N
HN
H
H
dD
dD
dD dA
Figure 4.23: Possible binding patterns of dD with dU, dG and dA.
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4.7 Outlook
From the insights we gained in the field of homo-C nucleotides and the
aminopyrimidine nucleotide dD in particular, countless new questions and
very interesting scientific challenges have arisen. As discussed in the last
chapter, homo-C nucleotide dD is partially able to mimic the natural nu-
cleotide dA and, therefore, these results open a completely new area of sci-
entific research. First of all, some open questions concerning the binding and
stacking ability of dD need to be answered. The nearest neighborhood effect
of dU, dA, and dD against dD must be investigated. In my opinion, the non-
self-complementary oligonucleotides that we have investigated in this work
are very suitable for such a disquisition. By varying the positions that flank
the nucleotide in the middle, where a purine should be exchanged for a purine
and a pyrimidine for a pyrimidine, the nearest neighborhood effect could be
determined qualitatively. Toward the same aim, a 5’-dC-[dD-dC]n-3’ strand,
and its complementary strand 3’-dG-[dU-dG]n-5’, should be synthesized to
verify the result that nucleotide dC is able to stabilize dD in a stacked con-
formation.
Furthermore, homo-C nucleotide dE should be synthesized and investigated
in the same oligonucleotide system. Presumably, it shows higher binding and
stacking abilities than dD, due to its higher molecular dipole which could
also lead to a higher nucleobase selectivity in binding.
At the next level, an all-pyrimidine system should be evaluated in order to
test the hypothesis of Siegel and Tor,1 which suggests an all-pyrimidine pro-
genitor of present-day DNA.
If we look further ahead, the possible range of application for such homo-C
nucleosides is unlimited. The effect of a dA to dD exchange could be investi-
gated in every context where adenosine occurs and participates in biochemical
processes. Possible targets could be ATP, NAD+, NADP+, FAD, or CoA, for
instance. As observed for some EANs and C-nucleotides, homo-C nucleosides
probably show antiviral or antibiotic activities (see sections 3.4 and 3.4.3).
Experimental Part
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Chapter 5
General
All reagents were used as purchased from commercial suppliers unless other-
wise stated. Solvents were purified and dried by conventional methods prior
to use. Thin-layer chromatography (TLC): Merck TLC aluminium sheets, sil-
ica gel 60 F254, 2mm. Column chromatography (CC): Sigma−Adrich Silica
gel Merck Type 9385, 230-400 mesh, 60 A˚. High-performance liquid chro-
matography (HPLC): Analytical HPLC: Shimadzu LC–10AT, Spherisorb R©-
NH2, 5 µm, 25cm×4.6mm. Preparative HPLC: Shimadzu LC–8A, Spheri-
sorb R©-NH2, 5 µm, 25cm×20mm. IR: Perkin − Elmer − 1600 FT-IR spec-
trometer; absorption values in cm−1 and intensity (s: strong, 0-30% transmis-
sion; m: middle, 30-60% transmission; w: weak, 60-100% transmission).1H-
and 13C-NMR: Bruker ARX–300, AV–400, DRX–500 or AV–600 instruments.
13C-signal multiplicity was deduced from DEPT 90 and DEPT 135 spec-
tra (Disortionless Enhancement by Polarization). Peak assignment was per-
formed by two-dimentional NMR experiment (NOESY, COSY, HSQC, HM-
BC). MS: Finnigan MAT–95 instrument for CI and EI; Finnigan TSQ–700
triple quadrupole spectrometer for ESI; m/z (rel. %); Bruker Autoflex I
spectrometer for MALDI-TOF. EA: Vario EL instrument (Elementar). UV
and UV-melting curves: Jacso J-715 spectrapolarimeter equipped with a Ju-
labo HS 18 temperature control unit in buffered solution (1 M NaCl, 0.01 M
TrisHCl buffer, pH = 7.0)
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Chapter 6
Synthesis
6.1 Methyl-3,5-di-O-benzyl-2-deoxy-α/β-D-
ribofuranosid (8)
According to the literature,178,220–222 8 was synthezised from 2-Deoxy-D-
ribose in good yields. An anomeric ratio of α/β 1.2:1 was observed. Anomers
could be separated by CC (SiO2, Hex/Et2O 1:1) and identified by NOESY
NMR.1
6.2 Methyl-3,5-di-O-benzoyl-2-deoxy-α/β-D-
ribofuranosid (14)
According to the literature,178 Methyl-2-deoxy-α/β-D-ribofuranosid 5 was
synthesized from 2-deoxy-D-ribose. 1.007 g 5 (7.508 mmol) was dissolved in
5 ml Pyr, cooled to 0 ◦C, and ,after adding BzCl (2.44 ml, 0.021 mol, 2.8
eq.), the reaction was stirred for 18 h at rt, followed by evaporation of Pyr.
Purification by CC (SiO2, Hex/Et2O 3:1) gave a anomeric mixture α/β 1.3:1
of 14 (2.305 g, 6.468 mmol, 86%).
1Anomers were separated for analysis, but mixture was used for further synthesis
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6.2. Methyl-3,5-di-O-Bz-2-deoxy-D-ribofuranosid (14) 95
Rf (SiO2, Hex/Et2O 3:1): 0.30 (β–14), 0.21 (α–14).
IR (film): 3650 w, 3063 w, 2992 w, 2954 m, 2932 m, 2834 w, 1969 w, 1915 w,
1721 s, 1602 m, 1584 w, 1491 w, 1451 m, 1375 m, 1315 m, 1271 s, 1210 m,
1176 m, 1113 s, 1069 s, 1026 m, 936 w, 858 w, 737 m, 711 s, 687 m.
1H-NMR (600 MHz, CDCl3): (β–14): 8.09 (dd, 3J = 8.3, 4J = 1.2, Hortho(Bz));
8.03 (dd, 3J = 8.3, 4J = 1.2, Hortho(Bz); 7.58 (dt, 3J = 7.5, 4J = 1.3, Hpara(Bz);
7.55 (dt, 3J = 7.5, 4J = 1.3, Hpara(Bz); 7.46–7.41 (m, Hmeta(Bz); 5.64–5.61
(m, HC(4)); 5.24 (dd, 3J = 5.4, 2.2, HC(1)); 4.58 (dd, 2J = 10.4, 3J = 5.1,
HC(5)); 4.56–4.54 (m, HC(3)); 4.50 (dd, 2J = 10.4, 3J = 5.3, HC(5)); 3.37 (s,
H3CO); 2.58 (ddd, 2J = 14.1, 3J = 7.3, 2.2, HC(2)); 2.36 (ddd, dt-like, 2J =
14.1, 3J = 5.4, HC(2)).
(α–14): 8.05 (dd, 3J = 7.1, 4J = 1.4, Hortho(Bz)); 8.03 (dd, 3J = 7.1, 4J = 1.4,
Hortho(Bz); 7.60–7.52 (m, Hpara(Bz)); 7.48–7.39 (m, Hmeta(Bz)); 5.46–4.42 (m,
HC(4); 5.20 (dd, 3J = 5.0, 2.2, HC(1)); 4.68–4.52 (m, HC(3), H2C(5)); 3.43
(s, H3CO); 2.58 (ddd, 2J = 14.6, 3J = 8.2, 5.0, HC(2)); 2.21 (ddd, 2J = 14.6,
3J = 2.2, 0.8, HC(2)).
13C-NMR (75.5 MHz, CDCl3): (β–14): 166.3, 166.1 (CO (Bz)), 133.3, 133.0
(Cpara(Bz)); 130.0, 129.8, 129.7 (Cipso, Cortho(Bz)); 128.5, 128.4 (Cmeta(Bz));
105.6 (C(1)); 81.9 (C(4)); 75.6 (C(3)); 65.3 (C(5)); 55.2 (CH3); 39.3 (C(2)).
(α–14): 166.4, 166.2 (CO (Bz)), 133.1, 133.1 (Cpara(Bz)); 129.9, 129.8, 129.7
(Cipso, Cortho(Bz)); 128.4 (Cmeta(Bz)); 105.1 (C(1)); 80.9 (C(4)); 74.8 (C(3));
64.5 (C(5)); 55.1 (CH3); 39.3 (C(2)).
ESI-MS: 379.1 (100, [M+Na]+).
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6.3 1-(3’,5’-di-O-Benzyl-2’-deoxy-α/β-D-
ribofurano-1-yl)-propan-2-one (10)
Freshly distilled SnCl4 (0.50 ml, 1.111 g, 4.263 mmol, 1.4 eq.) was added
under Ar dropwise at 0 ◦C to a well stirred solution of 8 (1.000 g, 3.045
mmol) and silylenolether180 (9) (0.476 g, 3.654 mmol, 1.2 eq.) in 40 ml dry
MeCN. After stirring for 45 min and allow the solution to warm up to rt,
MeCN was evaporated. The residue was dissolved in DCM and extracted
with sat. NaHCO3 solution, dried with MgSO4, and purified by CC (SiO2,
30 g, Hex/Et2O 1:1). 1.068 g 10 (3.015 mmol, 99%) of a α/β mixture was
optained as a yellowish oil. If starting with α–10 a α/β 5:1 and if starting
with a β–10 a α/β 2.7:1 mixture was observed. By treating the product with
Zn(OAc)2 (6.614 g, 30.132 mmol, 10 eq.) and NaOMe (1.628 g, 30.132 mmol,
10 eq.) in 50 ml MeOH for 2 d at rt the anomeric ratio could be shifted, in
both cases, to α/β 1:2.183
Rf (SiO2, Hex/Et2O 1:1): 0.21.
IR (film): 3407w, 3063m, 3030m, 2892s, 2863s, 1955w, 1877w, 1812w, 1713s,
1605w, 1586w, 1496m, 1453s, 1359s, 1309m, 1242m, 1205m, 1162m, 1098s,
1028s, 911m, 737s, 698s, 606w.
1H-NMR (600 MHz, CDCl3): 7.35–7.25 (m, arom. H); 4.56–4.46 (m, benz.
H, HC(1’), α/β-10); 4.20 (ddd, q-like, 3J = 4.4, HC(4’), α-10); 4.11 (ddd,
dt-like, 3J = 4.9, 2.6, HC(4’), β-10); 4.08 (ddd, dt-like, 3J = 7.0, 3.6, HC(3’),
α-10); 4.02 (ddd, dt-like, 3J = 6.3, 1.9, HC(3’), β-10); 3.53–3.42 (m, H2C(5’),
α/β -10); 2.93 (dd, 2J = 16.4, 3J = 6.8, HC(1), α-10); 2.78 (dd, 2J = 16.0,
3J = 6.9, HC(1), β-10); 2.65 (dd, 2J = 16.4, 3J = 6.5, HC(1), α-10); 2.58
(dd, 2J = 16.0, 3J = 5.8, HC(1), β-10); 2.37 (dt, 2J = 13.1, 3J = 6.7, HC(2’),
α-10); 2.2 (ddd, 2J = 13.1, 3J = 5.2, 1.3, HC(2’), β-10); 2.17 (s, H3C, β-10);
2.16 (s, H3C, α-10); 1.75 (ddd, 2J = 13.1, 3J = 5.6, 4.2, HC(2’), α-10); 1.61
6.4. (Di-O-Bz-2’-deoxy-D-ribofurano-1-yl)propan-2-one (15) 97
(ddd, 2J = 13.1, 3J = 10.2, 6.3, HC(2’), β-10).
13C-NMR (75.5 MHz, CDCl3): 207.2 (CO, α-10); 206.7 (CO, β-10); 138.1
(arom. Cquart., α/β-10); 128.3, 128.2, 125.7 (arom. C, α/β-10); 83.5, 80.9
(C(3’), C(4’), β-10); 82.4, 80.8 (C(3’), C(4’), α-10); 74.8 (C(1’), α-10); 74.6
(C(1’), β-10); 73.3 (C(5’), α/β-10); 71.4, 70.9, 70.8, 70.7 (benz. CH2, α/β-
10); 49.8 (C(2), α-10); 49.2 (C(2), β-10); 38.1 (C(2’), β-10); 37.7 (C(2’),
α-10); 30.7 (CH3, α-10); 30.5 (CH3, β-10).
ESI-MS: 377.2 (100, [M+Na]+).
6.4 1-(3’,5’-di-O-Benzoyl-2’-deoxy-α/β-D-
ribofurano-1-yl)-propan-2-one (15)
Freshly distilled SnCl4 (0.06 ml, 0.123 g, 0.471 mmol, 1.4 eq.) was added
under Ar dropwise at 0 ◦C to a well stirred solution of 14 (0.120 g, 0.337
mmol, α/β 1.3:1) and silylenolether180 9 (0.053 g, 0.404 mmol, 1.2 eq.) in 10
ml dry MeCN. After stirring for 45 min and allow the solution to warm up to
rt, MeCN was evaporated. The residue was dissolved in DCM and extracted
with sat. NaHCO3 solution, dried with Na2SO4 and purified by CC (SiO2, 5
g, Hex/Et2O 1:2). 0.037 g 15 (0.097 mmol, 29%, α/β 2:1) was optained as a
yellowish oil.
Rf (SiO2, Hex/Et2O 1:2): 0.27.
IR (film): 3045 w, 2966 m, 2930 m, 1961 w, 1912 w, 1729 s, 1717 s, 1613 m,
1591 w, 1444 m, 1372 w, 1343 w, 1332 m, 1282 m, 1254 w, 1209 w, 1198 w,
1124 s br, 965 m, 854 w, 831 w, 721 s, 699 s, 675 m.
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1H-NMR (600 MHz, CDCl3): 8.06–8.01 (m, Hortho(Bz)); 7.62–7.53 (m,
Hpara(Bz)); 7.48–7.27 (m, Hmeta(Bz)); 5.54–5.28 (m, HC(4’)); 4.72 (q, 3J =
6.6, HC(1’), α-15); 4.65–4.36 (m, H2C(5’), HC(3’), HC(1’) (β-15)); 2.99 (dd,
2J = 16.4, 3J = 7.0, HC(1), α-15); 2.88 (dd, 2J = 16.3, 3J = 6.9, HC(1),
β-15); 2.79–2.74 (m, HαC(2’), α/β-15); 2.73 (dd, 2J = 16.4, 3J = 6.3, HC(1),
α-15); 2.66 (dd, 2J = 16.3, 3J = 5.5, HC(1), β-15); 1.98 (ddd, 2J = 14.0, 3J
= 5.6, 3.7, HβC(2’), α-15); 1.95 (ddd, 2J = 14.0, 3J = 5.6, 3.6, HβC(2’), β-15).
13C-NMR (75.5 MHz, CDCl3): 206.3, 206.2 (C(2)); 166.1, 165.9 (CO(Bz));
133.3, 133.0 (Cpara(Bz)); 129.8, 129.7, 129.6, 129.5 (Cipso, Cortho(Bz)); 128.4,
128.3 (Cmeta(Bz)); 82.4, 81.4 (C(4’)); 76.8, 76.6 (C(1’)); 75.0, 74.9 (C(3’));
64.6, 64.5 (C(5’)); 49.6, 48.7 (C(1)); 38.5, 37.7 (C(2’)); 30.7, 30.5 (C(3)).
ESI-MS: 405.4 (100, [M+Na]+).
6.5 2-Amino-4-((3’,5’-di-O-benzyl-2’-deoxy-
β-D-ribofurano-1-yl)methyl)pyrimidine
(12β)
According to the literature,177,181 tBuOCH(NMe2)2 (0.369 g, 2.116 mmol, 1.5
eq.) was synthesized, added to a solution of 10 (0.500 g, 1.411 mmol) in
50 ml Toluene and stirred for 20 h at 70 ◦C. After solvent evaporation the
residue was dissolved in 16 ml EtOH, followed by addition of NaOEt (0.192
g, 2.822 mmol, 2 eq.) and stirred for 4 h at 60 ◦C.2 After cooling to 40 ◦C
Guanidinium sulfate (1.220 g, 5.643 mmol, 4 eq.) was added and reheated to
70 ◦C for 18 h. The solvent was evaporated and purification by CC (SiO2, 20
g, Hex/EE 1:8) gave 0.418 g of a yellowish oil, which was a mixture of desired
product anomers 12α/β (α/β 1:2) containing 12% of 2-Amino-4-methyl-5-
2The Enaminoketone intermediate was not isolated but detected by 13C-NMR and MS (see analysis).
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(3,5-di-O-benzyl-2-deoxy-α/β-pentofuranosyl)-pyrimidine. This me´lange was
separated by peparative HPLC (Hex/MeOH/EtOH 97:2:1) yielding 0.273 g
12β (0.923 mmol, 48%).
13C-NMR of Enaminoketon (75.5 MHz, CDCl3): 108.1, 107.4 (C(1)H)
ESI-MS of Enaminoketon: 432.3 (100, [M+Na]+).
Rf (SiO2, Hex/EE 1:8): 0.23.
EA: calc.: %C: 71.09, %H: 6.71, %O: 10.36; found: %C: 70.54, %H: 6.77,
%O: 9.81.
IR (film): 3325s, 3179m, 3087m, 3062m, 3029m, 2923m, 2862s, 1955w,
1887w, 1815w, 1629s, 1576s, 1495m, 1454s, 1362m, 1341m, 1266m, 1204m,
1094s, 1060s, 1027m, 912w, 812w, 736s, 697s, 604w.
1H-NMR (500 MHz, CDCl3): 8.14 (d, 3J = 5.1, HC(6); 7.37–7.24 (m, arom.
H); 6.55 (d, 3J = 5.1, HC(5)); 5.06 (s br, H2N); 4.54 (s, H2COC(5’)); 4.55–
4.46 (m, HC(1’)); 4.48 (s, H2COC(3’)); 4.13 (ddd, dt-like, 3J = 5.2, 2.6,
HC(4’)); 4.02 (ddd, dt-like, 3J = 6.7, 2.0, HC(3’)); 3.52 (dd, 2J = 10.1, 3J
= 4.7, HC(5’)); 3.42 (dd, 2J = 10.1, 3J = 5.4, HC(5’)); 2.89 (dd, 2J = 13.9,
3J = 6.9, HCC(4)); 2.75 (dd, 2J = 13.9, 3J = 5.7, HCC(4)); 2.10 (ddd, 2J
= 13.2, 3J = 5.2, 1.5, HαC(2’)); 1.72 (ddd, 2J = 13.2, 3J = 10.2, 6.3, HβC(2’)).
13C-NMR (125.8 MHz, CDCl3): 168.6 (C(4)); 162.9 (C(2)); 158.0 (C(6));
138.2, 138.1 (arom. Cquart.); 128.5, 128.4, 128.2, 127.8, 127.7, 127.6 (arom.
C); 111.6 (C(5)); 83.6 (C(4’)); 81.0 (C(3’)); 77.4 (C(1’)); 73.4 (COC(5’));
71.0 (COC(3’)); 70.9 (C(5’)); 43.4 (CC(4)); 38.0 (C(2’)).
ESI-MS: 428.2 (100, [M+Na]+).
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HPLC (Hex/MeOH/EtOH 97:2:1): tR = 22.1 min, k’ = 6.94, α21 = 1.10,
α32 = 1.08.
6.6 2-Amino-4-((3’,5’-di-O-benzyl-2’-deoxy-
α-D-ribofurano-1-yl)methyl)pyrimidine
(12α)
12α was obtained as a side product of the synthesis of 12β and isolated by
HPLC purification, as described in Section 6.5.
Rf (SiO2, Hex/EE 1:8): 0.23.
1H-NMR (600 MHz, CDCl3): 8.16 (d, 3J = 5.1, HC(6); 7.36–7.24 (m,
arom. H); 6.56 (d, 3J = 5.1, HC(5)); 4.95 (s br, H2N); 4.58–4.46 (m, HC(1’),
H2COC(3’), H2COC(5’)); 4.24 (ddd, q-like, 3J = 4.4, HC(4’)); 4.11 (ddd, 3J
= 6.8, 4.4, 3.7, HC(3’)); 3.52 (dd, 2J = 10.2, 3J = 4.7, HC(5’)); 3.47 (dd, 2J =
10.2, 3J = 4.9, HC(5’)); 3.02 (dd, 2J = 13.7, 3J = 7.5, HCC(4)); 2.79 (dd, 2J
= 13.7, 3J = 5.9, HCC(4)); 2.29 (ddd, dt-like, 2J = 13.0, 3J = 6.8, HαC(2’));
1.86 (ddd, 2J = 13.0, 3J = 6.1, 4.4, HβC(2’)).
13C-NMR (125.8 MHz, CDCl3): 168.5 (C(4)); 163.1 (C(2)); 157.9 (C(6));
138.2, 138.1 (arom. Cquart.); 128.5, 128.3, 127.7, 127.6(arom. C); 111.5
(C(5)); 83.6 (C(4’)); 81.4 (C(3’)); 77.4 (C(1’)); 73.3 (COC(5’)); 72.1 (COC(3’));
70.3 (C(5’)); 43.0 (CC(4)); 36.8 (C(2’)).
ESI-MS: 428.2 (100, [M+Na]+).
HPLC (Hex/MeOH/EtOH 97:2:1): tR = 23.5 min, k’ = 7.46, α32 = 1.08,
α43 = 1.17.
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6.7 2-Amino-4-methyl-5-(3’,5’-di-O-benzyl-
2’-deoxy-β-D-ribofurano-1-yl)pyrimidine
(13β)
13β was obtained as a side product of the synthesis of 12β and isolated by
HPLC purification, as described Section 6.5.
Rf (SiO2, Hex/EE 1:8): 0.23.
IR (KBr): 3339s, 3182s, 2906m, 2867m, 2837m, 1660s, 1594s, 1557s, 1488s,
1453m, 1364s, 1357s, 1313m, 1218m, 1187m, 1158m, 1102s, 1057s, 800m,
743s, 698s, 606m, 554m.
1H-NMR (600 MHz, CDCl3): 8.30 (s, HC(6)); 7.37–7.25 (m, arom. H); 5.16
(dd, 3J = 10.8, 5.2, HC(1’)); 5.06 (s br, H2N); 4.59 (d, 2J = 12.2, HCOC(5’));
4.55 (s br, H2COC(3’)); 4.52 (d, 2J = 12.2, HCOC(5’)); 4.24 (ddd, dt-like,
3J = 4.8, 2.4, HC(4’)); 4.18–4.15 (m, HC(3’)); 3.63 (dd, 2J = 10.1, 3J = 4.5,
HC(5’)); 3.55 (dd, 2J = 10.1, 3J = 5.1, HC(5’)); 2.35 (s, H3C); 2.31 (ddd, 2J
= 13.1, 3J = 5.2, 1.2, HαC(2’)); 1.87 (ddd, 2J = 13.1, 3J = 10.8, 6.1, HβC(2’)).
13C-NMR (75.5 MHz, CDCl3): 165.6 (C(2)); 162.0 (C(6)); 156.0 (C(4));
137.9 (Ctert(Bn)); 128.4, 128.3, 127.7, 127.6, 127.5 (arom. C); 122.2 (C(5));
83.6 (C(4’)); 81.2 (C(1’)); 75.4 (C(3’)); 73.4 (C(5’)); 71.1, 70.8 (benz. C);
39.2 (C(2’)); 21.6 (CH3).
ESI-MS: 428.2 (100, [M+Na]+).
HPLC (Hex/MeOH/EtOH 97:2:1): tR = 20.4 min, k’ = 6.32, α21 = 1.10.
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6.8 2-Amino-4-methyl-5-(3’,5’-di-O-benzyl-
2’-deoxy-α-D-ribofurano-1-yl)pyrimidine
(13α)
13α was obtained as a side product of the synthesis of 12β and isolated by
HPLC purification, as described Section 6.5.
Rf (SiO2, Hex/EE 1:8): 0.23.
1H-NMR (600 MHz, CDCl3): 8.37 (s, HC(6)); 7.37–7.25 (m, arom. H);
5.14 (dd, br t-like, 3J = 7.4, HC(1’)); 5.01 (s br, H2N); 4.60 (d, 2J = 12.2,
HCOC(5’)); 4.56 (d, 2J = 12.2, HCOC(5’)); 4.50 (s, H2COC(3’)); 4.34 (ddd,
q-like, 3J = 4.3, HC(4’)); 4.26 (ddd, 3J = 6.7, 5.6, 4.2, HC(3’)); 3.61 (dd, 2J
= 10.3, 3J = 4.3, HC(5’)); 3.59 (dd, 2J = 10.3, 3J = 4.5, HC(5’)); 2.58 (ddd,
dt-like, 2J = 12.8, 3J = 6.8, HβC(2’)); 2.35 (s, H3C); 1.98 (ddd, 2J = 12.8, 3J
= 8.1, 5.6, HαC(2’)).
ESI-MS: 428.2 (100, [M+Na]+).
HPLC (Hex/MeOH/EtOH 97:2:1): tR = 27.0 min, k’ = 8.72, α43 = 1.17.
6.9 2-Amino-4-((2’-deoxy-β-D-ribofurano-1-
yl)methyl)pyrimidine (1)
BBr3 (2.96 ml, 1M in DCM, 2.959 mmol, 6 eq.) was added at 0 ◦C to a
solution of 12β (0.200 g, 0.493 mmol) in 15 ml abs. DCM. The reaction was
quenched with 10 ml H2O after 3 min, neutralized with sat. NaHCO3 solu-
tion and extracted with DCM. The water phase was evaporated and purified
by CC (SiO2 , 3 g, EE/MeOH 10:1), yielding 0.110 g (0.488 mmol, 99%) of
1 as a white solide.
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Rf (SiO2, EE/MeOH 10:1): 0.10.
UV (H2O): λmax = 291.8, log * = 3.581; λmax = 225.7, log * = 4.057; λmax
= 185.8, log *= 4.013; λmin = 249.8, log *= 2.776; λmin = 206.6, log *= 3.721.
IR (KBr): 3342s, 3223s, 2922s, 2875s, 2136w, 1632s, 1582s, 1567s, 1468s,
1340m, 1269m, 1218m, 1168m, 1096s, 1048s, 909w, 876w, 804w, 781w, 714w.
1H-NMR (400 MHz, MeOD): 8.13 (d, 3J = 5.1, HC(6)); 6.64 (d, 3J = 5.1,
HC(5)); 4.52–4.45 (m, HC(1’)); 4.21 (ddd, dt-like, 3J = 6.2, 2.9, HC(4’)); 3.77
(ddd, dt-like, 3J = 4.8, 2.9, HC(3’)); 3.55 (dd, 2J = 11.7, 3J = 4.6, HC(5’));
3.51 (dd, 2J = 11.7, 3J = 5.2, HC(5’)); 2.83 (dd, 2J = 13.7, 3J = 7.3, HCC(4));
2.78 (dd, 2J = 13.7, 3J = 5.6, HCC(4)); 1.95 (ddd, 2J = 13.1, 3J = 5.5, 2.2,
HC(2’)); 1.82 (ddd, 2J = 13.1, 3J = 9.7, 6.2, HC(2’)).
13C-NMR (75.5 MHz, MeOD): 171.9 (C(4)); 165.7 (C(2)); 160.2 (C(6));
113.1 (C(5)); 90.1 (C(4’)); 79.9 (C(3’)); 75.2 (C(1’)); 65.2 (C(5’)); 45.6
(C(2’)); 43.0 (CC(4)).
ESI-MS: 226.0 (100, [M+H]+); 248.0 (77, [M+Na]+).
6.10 N-(4-((2’-deoxy-β-D-ribofurano-1-yl)-
methyl)pyrimidin-2-yl)benzamide (18)
A solution of 1 ( 0.100 g, 0.444 mmol) and TMSCl (0.28 ml, 2.220 mmol,
5 eq.) in 10 ml Pyr was stirred for 12 h at 0 ◦C, followed by addition of
BzCl (0.26 ml, 2.220 mmol, 5 eq.) and stirring for 12 h at rt.187 0.6 ml H2O
and 2 ml of aq. 25% NH3 solution was added to quench the reaction. The
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solvent was evaporated and the residue was extracted with Et2O and H2O.
The aqueous phase was evaporated and dried under HV. The obtained white
solid was purified by CC (SiO2, 2.5 g, EE/MeOH 10:1), giving 0.080 g (0.244
mmol, 55%) of 18.
Rf (SiO2, EE/MeOH 10:1): 0.12.
IR (KBr): 3406s, 2935m, 2526w, 2126w, 1686s, 1600s, 1529s, 1493m, 1441s,
1404s, 1341m, 1269s, 1192w, 1099m, 1076m, 1051m, 1002w, 905w, 796w,
713m.
1H-NMR (400 MHz, MeOD): 8.53 (d, 3J = 5.1, HC(6)); 8.02–7.97 (m, arom.
Hmeta); 7.62–7.43 (m, arom. Hortho,para); 7.18 (d, 3J = 5.1, HC(5)); 4.61–4.55
(m, HC(1’)); 4.22 (ddd, dt-like, 3J = 6.2, 2.5, HC(4’)); 3.79 (ddd, dt-like, 3J
= 4.9, 2.8, HC(3’)); 3.55 (dd, 2J = 11.7, 3J = 4.7, HC(5’)); 3.52 (dd, 2J =
11.7, 3J = 5.0, HC(5’)); 3.00 (d, 3J = 6.3, H2CC(4)); 1.99 (ddd, 2J = 13.1, 3J
= 5.5, 2.2, HαC(2’)); 1.86 (ddd, 2J = 13.1, 3J = 9.8, 6.1, HβC(2’)).
13C-NMR (75.5 MHz, MeOD): 171.2 (C(4)); 168.4 (CO); 159.0, 158.9 (C(2),
C(6)); 135.6, 133.6, 129.7, 129.1 (arom. C); 118.5 (C(5)); 89.0 (C(4’)); 78.4
(C(3’)); 73.9 (C(1’)); 63.9 (C(5’)); 44.2 (C(2’)); 41.7 (CC(4)).
ESI-MS: 330.3 (6, [M+H]+); 352.2 (100, [M+Na]+).
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6.11 N-(4-((5’-O-(4”,4”’-dimethoxytrityl)-2’-
deoxy-β-D-ribofurano-1-yl)methyl)pyri-
midin-2-yl)benzamide (19)
Compound 18 (0.057 g, 0.173 mmol), DMTCl (0.076 g, 0.225 mmol, 1.3 eq.)
and (Bu4N)ClO4 (0.071 g, 0.208 mmol, 1.2 eq.) were dried overnight under
HV. 3 ml Pyr was added and stirred at rt for 16 h. After evaporation of
Pyr the residue was dissolved in DCM and extracted with sat. NaHCO3 and
brine. The organic phase was dried with Na2SO4, filtrated and evaporated.
After CC (SiO2, 3 g, EE (0.5% Et3N)), 19 (0.085 g, 0.135 mmol, 78%) was
obtained as a white foam.
Rf (SiO2, EE (0.5% Et3N)): 0.18.
1H-NMR (300 MHz, DCM): 8.44 (d, 3J = 5.0, HC(6)); 7.86 (d, 3J = 7.1,
2 benz. H); 7.53 (t, 3J = 7.4, 1 benz. H); 7.46–7.17 (m, 11 arom. H); 6.98
(d, 3J = 5.0, HC(5)); 6.80 (d, 3J = 8.4, 4 arom. H); 4.58–4.54 (m, HC(1));
4.28 (ddd, dt-like, 3J = 6.0, 2.3, HC(4)); 3.89 (ddd, dt-like, 3J = 4.8, 2.7,
HC(3)); 3.74 (s, H3CO); 3.72–3.13 (m, H2C(5)); 3.10 (dd, 2J = 9.8, 3J = 4.8,
HCC(4)); 3.05 (dd, 2J = 9.8, 3J = 5.1, HCC(4)); 2.00 (ddd, 2J = 13.1, 3J =
5.5, 2.1, HαC(2)); 1.85 (ddd, 2J = 13.1, 3J = 9.8, 6.0, HβC(2)).
13C-NMR (75.5 MHz, DCM): 169.8 (C(4)); 165.3 (CON); 158.9 (Carom.OMe);
158.2 (C(6)); 158.0 (C(2)); 145.5 (Cipso(Ph)); 136.4 (Cipso(PhOMe)); 134.9
(Cipso(Bz)); 132.6 (Cpara(Bz)); 130.4 (Cortho(PhOMe)); 129.1, 128.5, 128.2,
127.9 (Cortho(Ph), Cmeta(Ph), Cortho(Bz), Cmeta(Bz)); 127.1 (Cpara(Ph)); 117.3
(C(5)); 113.4 (Cmeta(PhOMe)); 86.5 (C(4’)); 86.4 (Ctert(Tr)); 77.2 (C(3’));
74.3 (C(1’)); 65.0 (C(5’)); 55.6 (CH3O); 43.9 (CC(4)); 41.2 (C(2’)).
ESI-MS: 654.3 (100, [M+Na]+).
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HR-ESI-MS: calc. for C38H37N3O6Na ([M+Na]+) 654.2578; found 654.2578.
6.12 (1-((N2
′
-Benzoyl(2-aminopyrimidin-4-
yl))methyl)-5-O-(4,4-dimethoxytrityl)-
2-deoxy-β-D-ribofurano-1-yl)-β-cyano-
ethyl-N,N-diisopropyl phosphoramidite
(20)
NEt(iPr)2 (0.09 ml, 0.507 mmol, 4 eq.) and PCl(N(iPr)2)(OEtCN) (0.03 ml,
0.158 mmol, 1.25 eq.) were added dropwise under Ar to a solution of 19
(0.080 g, 0.127 mmol) in 2 ml abs. DCM at rt. After 2 h, the reaction
mixture was diluted with 5 ml of EE (0.5% Et3N) and extracted with 10%
Na2CO3 solution and brine, dried with MgSO4, evaporated and purified by
CC (SiO2, 3g, EE/Hex 2:1 (0.1% Et3N)), yielding 20 as a colourless oil (0.068
g, 0.0818 mmol, 64%).
Rf (SiO2, EE (0.1% Et3N)): 0.21, 0.15.
1H-NMR (300 MHz, DCM): 8.72, 8.69 (2 s br, NH); 8.50, 8.49 (2 d, 3J
= 5.0, HC(6’)); 7.88–7.85 (m, 2 benz. Hortho); 7.56 (t br, 3J = 7.4, benz.
Hpara); 7.49–7.18 (m, 11 arom. H); 7.05, 7.04 (2 d, 3J = 5.0, HC(5’)); 6.83,
6.82 (2 d, 3J = 8.8, HCmeta(PhOMe)); 4.60–4.53 (m, HC(1)); 4.46–4.39 (m,
HC(4)); 4.08–4.02 (m, HC(3)); 3.76, 3.75 (2 s, H3CO), 3.81–3.51 (m, H2C(5),
OCH2CH2CN); 3.16–3.00 (m, NCHMe2, H2CC(4’)); 2.57, 2.44 (2 t, 3J = 6.3,
OCH2CH2CN); 2.25–2.10 (m, HαC(2)); 1.91 (ddd, 2J = 13.0, 3J = 9.8, 6.1,
HβC(2)).
13C-NMR (75.5 MHz, DCM): 169.7 (C(4’)); 165.0 (CON); 159.0 (COMe);
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158.3, 158.0 (C(2’), C(6’)); 145.5 (Cipso(Ph)); 136.5 (Cipso,para(PhOMe));
135.1 (Cipso(Bz)); 132.5 (Cpara(Bz)); 130.5, 129.1, 128.6, 128.2, 127.9 (Cortho,
meta(Ph), Cortho,meta(Bz), Cortho(PhOMe)); 127.1 (Cpara(Ph)); 118.2, 118.1
(CN); 117.3 (C(5’)); 113.4 (Cmeta(PhOMe)); 86.4 (Ctert(Tr)); 86.0, 85.8 (C(4));
77.6, 77.5 (C(1)); 75.7, 75.5 (C(3)); 64.6 (C(5)); 58.8, 58.6 (CH2CH2CN); 55.6
(CH3O); 44.0 (CC(4’)); 43.6, 43.5 (CH3CHN); 40.4 (C(2)); 24.7 (CH3CHN);
21.3, 20.7 (CH2CH2CN).
ESI-MS: 854.4 (100, [M+Na]+).
6.13 2-Iodo-4-methyl-5-(3’,5’-di-O-benzyl-2’-
deoxy-α/β-D-ribofurano-1-yl)pyrimi-
dine (22α/β)
An anomeric mixture of 13α/β (0.069 g, 0.170 mmol), Isopentyl nitrite (0.07
ml, 0.510 mmol, 3 eq.), CH2I2 (0.07 ml, 0.851 mmol, 5 eq.), and CuI (32.4
mg, 0.170 mmol, 1 eq.) in 2 ml dry THF was refluxed under Ar for 1.5 h,
diluted with DCM and extracted with sat. NaCl solution. The organic phase
was dried with Na2SO4, filtrated and evaporated. CC (SiO2, 4 g, DCM/EE
20:1) gave 22 (0.017 g, 0.0329 mmol, 19.4%) as a brownish resin.
Rf (SiO2, DCM/EE 20:1): 0.18.
1H-NMR (300 MHz, CDCl3): 8.50, 8.49 (2 s, HC(6), α/β-22)); 7.38–7.26
(m, arom. H); 5.24–5.17 (m, HC(1’)); 4.61–4.54 (m, benz. H); 4.30–4.18 (m,
HC(3’), HC(4’)); 3.64–3.54 (m, H2C(5’)); 2.69–2.60 (m, HC(2’), α/β-22);
2.43 (s, H3C, α-22)); 2.39 (s, H3C, β-22)); 1.93 (ddd, 2J = 13.0, 3J = 6.2,
4.0, HC(2’), β-22); 1.81 (ddd, 2J = 13.0, 3J = 10.7, 5.9, HC(2’), α-22).
13C-NMR (75.5 MHz, CDCl3): 166.2, 164.5 (C(4)); 156.1, 155.9 (C(6));
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137.7 (Ctert(Bn)); 132.8, 131.3 (C(5)); 128.4, 128.3, 127.8, 127.7, 127.6,
127.5, 127.5 (C(2), arom. C); 84.0, 83.6 (C(4’)); 81.1, 80.6 (C(1’)); 75.3,
75.0 (C(3’)); 73.5 (CH2OC(3’)); 71.6, 71.3 (CH2OC(5’)); 70.8, 70.5 (C(5’));
39.4, 38.8 (C(2’)); 21.5 (CH3).
ESI-MS: 539.1 (100, [M+Na]+).
6.14 2-O-benzyl-4-methyl-5-(3’,5’-di-O-benz-
yl-2’-deoxy-α/β-D-ribofurano-1-yl)py-
rimidine (23α/β)
NaOH (9.8 mg, 0.097 mmol, 5 eq.) and BnOH (0.08 ml, 0.775 mmol, 40
eq.) were added to a solution of 22 (10 mg, 0.0194 mmol) in 1 ml MeCN.189
After stirring for 3.5 h at 85 ◦C under Ar, the solvent was evaporated and
the residue was purified by CC (SiO2, 1 g, EE/DCM 1:1), yielding 9.5 mg 23
(0.0192 mmol, 99%) as a colorless oil.
Rf (SiO2, EE/DCM 1:1): 0.18.
1H-NMR (300 MHz, CDCl3): 8.57, 8.52 (2 s, HC(6), α/β-23)); 7.60–7.26
(m, arom. H); 5.50, 5.42 (2 s, H2COC(2), α/β-23)); 5.24–5.19 (m, HC(1’));
4.58, 4.57, 4.56, 4.55 (4 s, benz. H); 4.29–4.25 (m, HC(4’)); 4.19–4.17 (m,
HC(3’)); 3.66–3.54 (m, H2C(5’)); 2.69–2.58 (m, HC(2’), β-23); 2.44 (s, H3C,
α-23)); 2.41 (s, H3C, β-23)); 2.39–2.33 (m, HC(2’), α-23); 2.03–1.92 (m,
HC(2’), β-23); 1.86 (ddd, 2J = 13.1, 3J = 10.8, 6.0, HC(2’), α-23).
13C-NMR (75.5 MHz, CDCl3): 167.8 (C(4)); 164.1 (C(2)); 157.6 (C(6));
137.8 (Ctert(Bn)); 137.1 (CtertCH2OC(2)); 128.4, 128.3, 128.2, 127.9, 127.7,
127.6, 127.6 (arom. C); 126.4 (C(5)); 84.1 (C(4’)); 80.9 (C(1’)); 75.2 (C(3’));
73.4, 71.2, 70.7, 68.7 (benz. CH2, C(5’)); 39.4 (C(2’)); 21.8 (CH3).
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ESI-MS: 497.6 (31, [M+H]+), 519.2 (100, [M+Na]+), 535.1 (9, [M+K]+).
6.15 4-methyl-5-(2’-deoxy-α/β-D-ribofurano-
1-yl)pyrimidin-2-one (24α/β)
BBr3 (96.7 µl, 0.0967 mmol, 6 eq.) was added to a solution of 23 (8 mg,
0.0161 mmol) in 1.3 ml dry CH2Cl2 at 0 ◦C.223 The reaction was quenched
with 0.6 ml H2O after 3 min and neutralized with sat. NaHCO3. After phase
separation, the aqueous solution was evaporated and filtrated over SiO2 (0.5
g, DCM/MeOH 10:1), giving 24 (3.6 mg, 0.0159 mmol, 99%) as a white solid.
Rf (SiO2, DCM/MeOH 10:1): 0.28.
1H-NMR (300 MHz, MeOD): 8.21 (s br, HC(6)); 5.01–5.04 (m, HC(1’));
4.39–4.24 (m, HC(3’), HC(4’)); 3.62–3.56 (m, H2C(5’)); 2.63–2.55 (m, HC(2’),
β-24); 2.38–2.31 (m, HC(2’), α-24); 2.35 (s, H3C, α-24)); 2.33 (s, H3C, β-
24)); 2.20–12 (m, HC(2’), β-24); 1.94–1.85 (m, HC(2’), α-24).
ESI-MS: 227.0 (100, [M+H]+), 249.0 (38, [M+Na]+), 265.0 (9, [M+K]+).
6.16 Synthesis of Silyl Protected 2-deoxy-D-
ribono-1,4-lactones
The two silyl protected lactones 3,5-Di-O-((tbutyldimethylsilyl)-2-deoxy-D-
ribono-1,4-lactone (26a) and 3,5-O-((1’,1’,3’,3’-Tetraisopropyl)disiloxandiyl)-
2-deoxy-D-ribono-1,4-lactone (26b) were synthesized from commercially avail-
able 2-Deoxy-D-ribose in good yields, according to the literature.162,201,202
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6.17 4-((Z)-4’,6’-Di-O-(tbutyldimethylsilyl)-
2’,4’,5’,6’-tetrahydroxyhex-1’-en-1’-yl)-
pyrimidin-2(1H)-one (30a)
n-BuLi (0.49 ml 2M in Heptan, 0.972 mmol, 3.5 eq.) was added to freshly
distilled NH(iPr)2 (0.07 ml, 0.972 mmol, 3.5 eq.) in 3 ml Et2O at 0 ◦C, stirred
for 30 min and admixed to a suspension of 4-Methylpyrimidin-2-one (0.045
g, 0.305 mmol, 1.1 eq.) in 7 ml THF at –78 ◦C. After 1 h, the suspension
was allowed to warm up to 0 ◦C and 26a (0.100 g, 0.278 mmol) was added
as a solid. The mixture was reacted overnight, quenched with 0.2 ml MeOH
and extracted with 1M NH4Cl and DCM. The organic phase was dried with
Na2SO4, filtrated and evaporated. Purification by CC (3g SiO2, EE/DCM
1:1) gave 30a as a yellow solid (0.033 g, 0.0701 mmol, 25%).
Rf (SiO2, EE/DCM 1:1): 0.33.
1H-NMR (400 MHz, CDCl3): 12.64, 12.60 (2 s, HOC(2’)); 7.25 (s br, NH);
6.87 (d, 3J = 7.4, HC(6), (3H)-Pyr); 6.87 (dd, 3J = 7.4, 10.3, HC(6), (1H)-
Pyr); 5.55, 5.53 (2 d, 3J = 7.4, HC(5), (1H)/(3H)-Pyr); 5.23 (s, HC(1’));
4.22–4.10, 3.68-3.58 (2 m, HC(4’), HC(5’), H2C(6’), HOC(5’)); 2.67–2.46 (m,
H2C(3’)); 0.89, 0.88, 0.87, 0.84 (4 s, H3C(tBu)); 0.08, 0.07, 0.06, 0.05 (4 s,
H3CSi).
13C-NMR (100.6 MHz, CDCl3): 199.9, 198.6 (C(2’)); 151.6, 151.1, 150.4,
150.2 (C(4), C(2)); 135.9, 135.7 (C(6)); 101.6 (C(1’), (3H)-Pyr); 95.6, 94.9
(C(5)); 74.9 (C(1’), (1H)-Pyr); 71.2 (C(5’)); 70.3 (C(4’)); 65.3, 63.7 (C(6’));
46.5, 44.4 (C(3’)); 25.8, 25.7 (CH3(tBu)); 18.2, 18.0 (C(CH3)3); -4.5, -4.8,
-5.5, -5.6 (CH3Si).
ESI-MS: 471.3 (20, [M+H]+); 493.3 (100, [M+Na]+); 509.3 (11, [M+K]+).
6.18. Coupled Disiloxandiyl Protected Pyrimidin-2-one (30B) 111
HR-ESI-MS: calc. for C22H42N2O5Si2Na ([M+Na]+) 493.2524; found 493.2526.
6.18 4-((Z)-4’,6’-O-((1”,1”,3”,3”-Tetraiso-
propyl)disiloxandiyl)-2’,4’,5’,6’-tetra-
hydroxyhex-1’-en1’-yl)pyrimidin-2(1H)-
one (30b)
n-BuLi (0.49 ml 2M in Heptan, 0.972 mmol, 3.6 eq.) was added to freshly
distilled NH(iPr)2 (0.07 ml, 0.972 mmol, 3.6 eq.) in 3 ml Et2O at 0 ◦C, stirred
for 30 min and admixed to a suspension of 4-Methylpyrimidin-2-one (0.045
g, 0.305 mmol, 1.14 eq.) in 7 ml THF at –78 ◦C. After 1 h, the suspension
was allowed to warm up to 0 ◦C and 26b (0.100 g, 0.267 mmol) was added
as a solid. The mixture was reacted overnight, quenched with 0.2 ml MeOH
and extracted with 1M NH4Cl and DCM. The organic phase was dried with
Na2SO4, filtrated and evaporated. Purification by CC (3g SiO2, EE/DCM
1:1) gave 30b as a yellow solid (0.033 g, 0.0681 mmol, 25%).
Rf (SiO2, EE/DCM 1:1): 0.25.
1H-NMR (400 MHz, CDCl3): 12.64 (s, HOC(2’)); 10.17 (s br, HN(1)); 6.91
(dd, 3J = 7.4, 5.5, HC(6)); 5.55 (d, 3J = 7.4, HC(5)); 5.27 (s, HC(1’)); 4.24
(ddd, dt-like, 3J = 9.1, 5.3, HC(4’)); 4.13 (dd, 2J = 11.7, 3J = 1.1, HC(6’));
3.80 (dd, 2J = 11.7, 3J = 1.9, HC(6’)); 3.36 (ddd, d br-like, 3J = 9.1, HC(5’));
2.90 (dd, 2J = 14.8, 3J = 4.8, HC(3’)); 2.65 (dd, 2J = 14.8, 3J = 5.8, HC(3’));
1.09–0.95 (m, 28 H (iPr)).
13C-NMR (100.6 MHz, CDCl3): 197.8 (C(2’)); 151.6, 150.1 (C(2), C(4));
135.9 (C(6)); 101.6 (C(1’)); 95.4 (C(5)); 75.3 (C(4’)), 67.8 (C(5’)); 62.3
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(C(6’)); 48.6 (C(3’)); 17.4, 17.2, 17.2, 17.1 (CH3(iPr)); 13.3, 13.0, 12.5, 12.4
(CH(iPr)).
ESI-MS: 485.7 (14, [M+H]+); 507.7 (100, [M+Na]+); 523.8 (6, [M+K]+).
6.19 Synthesis of CE PA dU (31)
According to the literature,48,187 Cyanoethylphosphoramidite dU (31) was
synthesized, in two steps, from commercially available 2’-Deoxyuridine in
good yields.
6.20 Synthesis of Oligonucleotides
According to Applied Biosystems, oligonucleotides were synthesized on a
DNA-synthesizer (Expedite NAS 8905, Applied Biosystems) in 0.4 µmol scale
using standard specifications and protocol for automated 3’→5’ synthesis.
Following modifications were made: In order to spend less building blocks,
the phosphoramidite concentrations were reduced from 0.1M to 0.05M. Fur-
thermore, the more acidic and more potent 5-(ethylthio)-1H-tetrazole was
used as activator, instead of 1H-tetrazole. In addition, the coupling times for
our artificial nucleotide dD were elongated from 90 sec. to 12 min. Oligonu-
cleotide syntheses were performed starting from commercially available nu-
cleosides, bound to controled pore glas 500 (CPG 500, Glen research). The
corresponding commercially available cyanoethyl phosphoramidites were used
for the insertion of dA, dG and dC.
The oligonucleotide elongation cycle consisted of four steps:
1) Acidic cleavage of the 5’-end DMT protecting group of the support-
bound nucleoside (respectively oligonucleotide).
2) Coupling with 5-(ethylthio)-1H-tetrazole activated (2-cyanoethyl)-
phosphoramidite.
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3) Capping of uncoupled 5’-OH-groups with Ac2O.
4) Oxidation of the phospite to phosphate with aq. I2-solution.
After finishing chain elongation and cleavage of the 5’-terminal DMT protec-
tion group, the oligonucleotides were treated with oversaturated aq. NH3-
solution at 50 ◦C for 20 h to release it from solid support and to chip all nu-
cleobase and phosphate protecting groups. The crude oligonucleotides were
purified by precipitation from 70% EtOH/ 30% 0.3M aq. Na-acetate, pH =
4.8 and analysed by HPLC and MALDI-TOF-MS (matrix-assisted laser des-
orption/ionization time-of-flight MS, Matrix: 3-HPA, if not otherwise noted).
HPLC was performed on a DEAE-ion exchange (IE) column (Nucleogen-
DEAE 60-7, Macherey-Nagel) with a linear KCl-gradient in 20 mM KH2PO4,
pH = 6.0, in H2O/CH3CN 4:1. If necessary oligonucleotides were purified
by the same HPLC method. Yields were determined by photometric DMT
cation detection in DMT cleavage fractions, collected from synthesizer. In
addition, the results were confirmed by determinations of oligonucleotide con-
centration after work up and purification. The oligonucleotide concentrations
were determined by the Lambert-Beer law measuring the optical density at
260 nm and assuming the extinction coefficients ε to be the sum of ε of all
mononucleosides at the same wavelength. These measurements were carried
out at 90 ◦C in oder to ensure this assumption to be true, because stack-
ing of the nucleobases, and, therefore, hypochromicity are suspended at this
temperature.
6.20.1 5’–CGCAUGAGUACGC–3’ (A1)
Scale: 0.4 µmol dC-CPG 500
Synthesis protocol: 1 µmol
Yield: 90%
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MALDI-TOF-MS: 3930 (77, [M+11H]−); 3952 (100, [M+Na+10H]−); 3972
(82, [M+2Na+9H]−); 3996 (49, [M+3Na+8H]−).
HPLC: tR = 25.04 min, k’ = 20.40.
5'-CGCAUGAGUACGC-3'
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Figure 6.1: HPLC of crude A1.
6.20.2 5’–CGCAUGDGUACGC–3’ (A2)
Scale: 0.4 µmol dC-CPG 500
Synthesis protocol: 1 µmol
Yield: 37.3% 3
dD-CE PA coupling: - Coupling time: 12 min
- Yield: 75.2%
MALDI-TOF-MS: 3905 (91, [M+11H]−); 3927 (100, [M+Na+10H]−); 3949
(65, [M+2Na+9H]−); 3971 (49, [M+3Na+8H]−); 3993 (12, [M+4Na+7H]−).
3Low yielded couplings with dD-CE PA and dG-CE PA.
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HPLC: tR = 25.91 min, k’ = 24.16.
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Figure 6.2: HPLC of crude A2.
6.20.3 5’–CGCAUGGGUACGC–3’ (A3)
Scale: 0.4 µmol dC-CPG 500
Synthesis protocol: 1 µmol
Yield: 95%
MALDI-TOF-MS: 3946 (63, [M+11H]−); 3968 (100, [M+Na+10H]−); 3990
(78, [M+2Na+9H]−); 4012 (45, [M+3Na+8H]−).
HPLC: tR = 24.34 min, k’ = 19.80.
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5'-CGCAUGGGUACGC-3'
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Figure 6.3: HPLC of crude A3.
6.20.4 5’–CGCAUGUGUACGC–3’ (A4)
Scale: 0.4 µmol dC-CPG 500
Synthesis protocol: 1 µmol
Yield: 96%
MALDI-TOF-MS: 3907 (100, [M+11H]−); 3929 (8, [M+Na+10H]−).
HPLC: tR = 24.22 min, k’ = 19.70.
6.20. Synthesis of Oligonucleotides 117
5'-CGCAUGUGUACGC-3'
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Figure 6.4: HPLC of crude A4.
6.20.5 5’–CGCAUGCGUACGC–3’ (A5)
Scale: 0.4 µmol dC-CPG 500
Synthesis protocol: 1 µmol
Yield: 99%
MALDI-TOF-MS: 3906 (98, [M+11H]−); 3928 (100, [M+Na+10H]−); 3950
(61, [M+2Na+9H]−); 3972 (30, [M+3Na+8H]−); 3994 (13, [M+4Na+7H]−).
HPLC: tR = 24.47 min, k’ = 19.91.
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5'-CGCAUGCGUACGC-3'
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Figure 6.5: HPLC of crude A5.
6.20.6 5’–GCGUACACAUGCG–3’ (B1)
Scale: 0.4 µmol dG-CPG 500
Synthesis protocol: 1 µmol
Yield: 90%
MALDI-TOF-MS: 3930 (100, [M+11H]−); 3952 (34, [M+Na+10H]−); 3974
(10, [M+2Na+9H]−).
HPLC: tR = 25.36 min, k’ = 20.68.
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Figure 6.6: HPLC of crude B1.
6.20.7 5’–GCGUACDCAUGCG–3’ (B2)
Scale: 0.4 µmol dG-CPG 500
Synthesis protocol: 1 µmol
Yield: 67.1% 4
dD-CE PA coupling: - Coupling time: 12 min
- Yield: 77.2%
MALDI-TOF-MS: 3904 (100, [M+11H]−); 3926 (56, [M+Na+10H]−); 3948
(16, [M+2Na+9H]−); 3970 (5, [M+3Na+8H]−).
HPLC: tR = 25.97 min, k’ = 22.40.
4Low yielded couplings with dD-CE PA and dG-CE PA.
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5'-GCGUACDCAUGCG-3'
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Figure 6.7: HPLC of crude B2.
6.20.8 5’–GCGUACGCAUGCG–3’ (B3)
Scale: 0.4 µmol dG-CPG 500
Synthesis protocol: 1 µmol
Yield: 78%
MALDI-TOF-MS: 3946 (100, [M+11H]−); 3968 (45, [M+Na+10H]−); 3990
(13, [M+2Na+9H]−); 4012 (7, [M+3Na+8H]−).
HPLC: tR = 24.41 min, k’ = 19.86.
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5'-GCGUACGCAUGCG-3'
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Figure 6.8: HPLC of crude B3.
6.20.9 5’–GCGUACUCAUGCG–3’ (B4)
Scale: 0.4 µmol dG-CPG 500
Synthesis protocol: 1 µmol
Yield: 94%
MALDI-TOF-MS: 3907 (100, [M+11H]−); 3929 (18, [M+Na+10H]−).
HPLC: tR = 23.92 min, k’ = 19.44.
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5'-GCGUACUCAUGCG-3'
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Figure 6.9: HPLC of crude B4.
6.20.10 5’–GCGUACCCAUGCG–3’ (B5)
Scale: 0.4 µmol dG-CPG 500
Synthesis protocol: 1 µmol
Yield: 99%
MALDI-TOF-MS: 3906 (100, [M+11H]−); 3928 (37, [M+Na+10H]−).
HPLC: tR = 25.45 min, k’ = 20.75.
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Figure 6.10: HPLC of crude B5.
6.20.11 5’–GUACGC–3’ (32)
Scale: 0.4 µmol dC-CPG 500
Synthesis protocol: 1 µmol
Yield: 53% 5
MALDI-TOF-MS6: 1777 (100, [M+4H]−); 1799 (5, [M+Na+3H]−); 1815
(2, [M+K+3H]−).
HPLC: tR = 12.16 min, k’ = 11.41.
5Low yielded couplings with dG-CE PA.
6Matrix: ATT.
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5'-GUACGC-3'
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Figure 6.11: HPLC of crude 32.
6.20.12 5’–CAUGCG–3’ (33)
Scale: 0.4 µmol dG-CPG 500
Synthesis protocol: 1 µmol
Yield: 81% 7
MALDI-TOF-MS8: 1777 (100, [M+4H]−); 1799 (10, [M+Na+3H]−); 1815
(2, [M+K+3H]−).
HPLC: tR = 12.33 min, k’ = 11.58.
7Low yielded couplings with dG-CE PA.
8Matrix: ATT.
6.20. Synthesis of Oligonucleotides 125
5'-CAUGCG-3'
-2
0
2
4
6
8
10
0 5 10 15 20 25 30 35
Retention Time [min]
m
A
U
Figure 6.12: HPLC of crude 33.
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7.1 Base pairing of A1B1
5’– C G C A U G A G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C A C A U G C G –5’
Figure 7.1: Double stranded oligonucleotide A1B1.
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Figure 7.2: Fraction folded plot of A1B1.
Table 7.1: Tm and thermodynamic data of A1B1.
Concentration [µM] 8.75 6.56 4.92 3.69
Tm [◦C] 56.2 55.4 54.6 53.8
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -14.9 -76.4 -206 0.999
1/T vs. ln Ka -14.9 ± 0.1 -76.8 ± 1.5 -208 ± 5
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7.2 Base pairing of A1B2
5’– C G C A U G A G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C D C A U G C G –5’
Figure 7.3: Double stranded oligonucleotide A1B2.
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Figure 7.4: Fraction folded plot of A1B2.
Table 7.2: Tm and thermodynamic data of A1B2.
Concentration [µM] 15.56 9.75 6.08 3.80
Tm [◦C] 52.5 51.6 50.0 48.6
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -13.6 -73.5 -201 0.988
1/T vs. ln Ka -13.9 ± 0.2 -76.8 ± 1.0 -211 ± 3
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7.3 Base pairing of A1B3
5’– C G C A U G A G U A C G C –3’
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...
...
...
...
...
...
3’– G C G U A C G C A U G C G –5’
Figure 7.5: Double stranded oligonucleotide A1B3.
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Figure 7.6: Fraction folded plot of A1B3.
Table 7.3: Tm and thermodynamic data of A1B3.
Concentration [µM] 9.73 6.08 3.8
Tm [◦C] 53.4 51.4 49.8
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -12.5 -55.2 -143 0.996
1/T vs. ln Ka -12.6 ± 0.3 -57.5 ± 2.50 -151 ± 7
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7.4 Base pairing of A1B4
5’– C G C A U G A G U A C G C –3’
...
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...
...
...
...
...
...
...
3’– G C G U A C U C A U G C G –5’
Figure 7.7: Double stranded oligonucleotide A1B4.
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Figure 7.8: Fraction folded plot of A1B4.
Table 7.4: Tm and thermodynamic data of A1B4.
Concentration [µM] 11.67 7.29 4.56 2.85
Tm [◦C] 64.1 63 61.8 60.8
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -18.5 -94.5 -255 0.999
1/T vs. ln Ka -18.5 ± 0.2 -94.7 ± 1.1 -256 ± 3
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7.5 Base pairing of A1B5
5’– C G C A U G A G U A C G C –3’
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...
3’– G C G U A C C C A U G C G –5’
Figure 7.9: Double stranded oligonucleotide A1B5.
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
25 30 35 40 45 50 55 60 65 70
T [°C]
F
r
a
c
ti
o
n
 f
o
ld
e
d
9.73 µM
6.08 µM
3.80 µM
2.73 µM
Figure 7.10: Fraction folded plot of A1B5.
Table 7.5: Tm and thermodynamic data of A1B5.
Concentration [µM] 9.73 6.08 3.80 2.73
Tm [◦C] 52.8 51.6 49.6 48.6
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -13.1 -62.0 -164 0.990
1/T vs. ln Ka -13.0 ± 0.3 -62.7 ± 1.9 -167 ± 6
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7.6 Base pairing of A2B1
5’– C G C A U G D G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C A C A U G C G –5’
Figure 7.11: Double stranded oligonucleotide A2B1.
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Figure 7.12: Fraction folded plot of A2B1.
Table 7.6: Tm and thermodynamic data of A2B1.
Concentration [µM] 9.12 6.84 5.13 3.85
Tm [◦C] 54.2 52.9 52.0 50.9
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -12.8 -56.7 -147 0.996
1/T vs. ln Ka -12.7 ± 0.1 -57.0 ± 0.8 -148 ± 3
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7.7 Base pairing of A2B2
5’– C G C A U G D G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C D C A U G C G –5’
Figure 7.13: Double stranded oligonucleotide A2B2.
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Figure 7.14: Fraction folded plot of A2B2.
Table 7.7: Tm and thermodynamic data of A2B2.
Concentration [µM] 15.56 11.67 8.75 6.56
Tm [◦C] 50.8 49.6 48.8 47.6
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -11.9 -56.7 -151 0.994
1/T vs. ln Ka -11.8 ± 0.1 -56.1 ± 0.3 -149 ± 1
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7.8 Base pairing of A2B3
5’– C G C A U G D G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C G C A U G C G –5’
Figure 7.15: Double stranded oligonucleotide A2B3.
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Figure 7.16: Fraction folded plot of A2B3.
Table 7.8: Tm and thermodynamic data of A2B3.
Concentration [µM] 15.56 9.73 6.08
Tm [◦C] 49.8 48.0 46.0
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -11.3 -50.9 -133 0.998
1/T vs. ln Ka -11.4 ± 0.2 -54.2 ± 3.4 -144 ± 10
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7.9 Base pairing of A2B4
5’– C G C A U G D G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C U C A U G C G –5’
Figure 7.17: Double stranded oligonucleotide A2B4.
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Figure 7.18: Fraction folded plot of A2B4.
Table 7.9: Tm and thermodynamic data of A2B4.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 56.6 54.8 53.2 51.3
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -12.8 -56.7 -147 0.999
1/T vs. ln Ka -12.6 ± 0.2 -54.3 ± 2.1 -140 ± 6
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7.10 Base pairing of A2B5
5’– C G C A U G D G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C C C A U G C G –5’
Figure 7.19: Double stranded oligonucleotide A2B5.
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Figure 7.20: Fraction folded plot of A2B5.
Table 7.10: Tm and thermodynamic data of A2B5.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 53.0 50.2 48.6 46.6
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -11.5 -47.3 -120 0.988
1/T vs. ln Ka -11.4 ± 0.1 -48.3 ± 1.3 -124 ± 4
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7.11 Base pairing of A3B1
5’– C G C A U G G G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C A C A U G C G –5’
Figure 7.21: Double stranded oligonucleotide A3B1.
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Figure 7.22: Fraction folded plot of A3B1.
Table 7.11: Tm and thermodynamic data of A3B1.
Concentration [µM] 15.56 9.73 3.80
Tm [◦C] 60.6 59.0 55.8
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -14.1 -64.0 -167 0.997
1/T vs. ln Ka -14.2 ± 0.3 -64.9 ± 2.4 -170 ± 7
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7.12 Base pairing of A3B2
5’– C G C A U G G G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C D C A U G C G –5’
Figure 7.23: Double stranded oligonucleotide A3B2.
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Figure 7.24: Fraction folded plot of A3B2.
Table 7.12: Tm and thermodynamic data of A3B2.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 53.8 52.2 51.2 50.0
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -14.4 -79.4 -218 0.995
1/T vs. ln Ka -14.2 ± 0.2 -77.1 ± 1.2 -211 ± 4
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7.13 Base pairing of A3B3
5’– C G C A U G G G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C G C A U G C G –5’
Figure 7.25: Double stranded oligonucleotide A3B3.
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Figure 7.26: Fraction folded plot of A3B3.
Table 7.13: Tm and thermodynamic data of A3B3.
Concentration [µM] 15.56 9.73 6.08
Tm [◦C] 56.0 54.6 53.1
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -13.8 -68.5 -183 0.999
1/T vs. ln Ka -13.8 ± 0.3 -67.6 ± 2.9 -181 ± 9
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7.14 Base pairing of A3B4
5’– C G C A U G G G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C U C A U G C G –5’
Figure 7.27: Double stranded oligonucleotide A3B4.
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Figure 7.28: Fraction folded plot of A3B4.
Table 7.14: Tm and thermodynamic data of A3B4.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 57.4 56.4 55.0 54.0
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -15.8 -86.3 -237 0.995
1/T vs. ln Ka -16.0 ± 0.3 -87.9 ± 1.6 -241 ± 5
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7.15 Base pairing of A3B5
5’– C G C A U G G G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C C C A U G C G –5’
Figure 7.29: Double stranded oligonucleotide A3B5.
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Figure 7.30: Fraction folded plot of A3B5.
Table 7.15: Tm and thermodynamic data of A3B5.
Concentration [µM] 9.73 6.08 3.80 2.38
Tm [◦C] 67.1 66.4 64.0 62.4
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -17.8 -82.7 -218 0.993
1/T vs. ln Ka -18.2 ± 0.4 -86.3 ± 3.0 -229 ± 8
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7.16 Base pairing of A4B1
5’– C G C A U G U G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C A C A U G C G –5’
Figure 7.31: Double stranded oligonucleotide A4B1.
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Figure 7.32: Fraction folded plot of A4B1.
Table 7.16: Tm and thermodynamic data of A4B1.
Concentration [µM] 9.73 6.08 3.80 2.38
Tm [◦C] 64.5 63.4 61.9 60.9
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -17.8 -86.3 -230 0.994
1/T vs. ln Ka -18.1 ± 0.1 -88.6 ± 0.9 -237 ± 3
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7.17 Base pairing of A4B2
5’– C G C A U G U G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C D C A U G C G –5’
Figure 7.33: Double stranded oligonucleotide A4B2.
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Figure 7.34: Fraction folded plot of A4B2.
Table 7.17: Tm and thermodynamic data of A4B2.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 57.0 55.8 54.7 53.3
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -15.4 -82.7 -226 0.997
1/T vs. ln Ka -15.2 ± 0.1 -80.9 ± 1.0 -220 ± 3
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7.18 Base pairing of A4B3
5’– C G C A U G U G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C G C A U G C G –5’
Figure 7.35: Double stranded oligonucleotide A4B3.
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Figure 7.36: Fraction folded plot of A4B3.
Table 7.18: Tm and thermodynamic data of A4B3.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 56.2 55.0 53.6 52.6
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -15.3 -82.7 -226 0.996
1/T vs. ln Ka -15.5 ± 0.2 -84.1 ± 1.3 -230 ± 4
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7.19 Base pairing of A4B4
5’– C G C A U G U G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C U C A U G C G –5’
Figure 7.37: Double stranded oligonucleotide A4B4.
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Figure 7.38: Fraction folded plot of A4B4.
Table 7.19: Tm and thermodynamic data of A4B4.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 55.6 53.8 52.6 51.6
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -14.5 -76.4 -207 0.982
1/T vs. ln Ka -14.6 ± 0.2 -77.9 ± 2.0 -212 ± 6
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7.20 Base pairing of A4B5
5’– C G C A U G U G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C C C A U G C G –5’
Figure 7.39: Double stranded oligonucleotide A4B5.
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Figure 7.40: Fraction folded plot of A4B5.
Table 7.20: Tm and thermodynamic data of A4B5.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 53.2 51.8 50.6 49.0
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -13.5 -70.9 -193 0.997
1/T vs. ln Ka -13.5 ± 0.2 -70.5 ± 2.3 -191 ± 7
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7.21 Base pairing of A5B1
5’– C G C A U G C G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C A C A U G C G –5’
Figure 7.41: Double stranded oligonucleotide A5B1.
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Figure 7.42: Fraction folded plot of A5B1.
Table 7.21: Tm and thermodynamic data of A5B1.
Concentration [µM] 12.16 9.73 6.08 3.80
Tm [◦C] 53.0 52.5 51.1 49.6
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -13.6 -70.9 -192 0.997
1/T vs. ln Ka -13.6 ± 0.1 -70.8 ± 1.0 -192 ± 3
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7.22 Base pairing of A5B2
5’– C G C A U G C G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C D C A U G C G –5’
Figure 7.43: Double stranded oligonucleotide A5B2.
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Figure 7.44: Fraction folded plot of A5B2.
Table 7.22: Tm and thermodynamic data of A5B2.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 49.3 48.0 46.6 45.1
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -12.6 -68.5 -188 0.999
1/T vs. ln Ka -12.8 ± 0.1 -70.3 ± 1.5 -193 ± 5
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7.23 Base pairing of A5B3
5’– C G C A U G C G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C G C A U G C G –5’
Figure 7.45: Double stranded oligonucleotide A5B3.
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Figure 7.46: Fraction folded plot of A5B3.
Table 7.23: Tm and thermodynamic data of A5B3.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 68.4 67.6 65.8 64.4
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -17.6 -79.4 -207 0.980
1/T vs. ln Ka -17.5 ± 0.1 -79.4 ± 0.8 -208 ± 2
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7.24 Base pairing of A5B4
5’– C G C A U G C G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C U C A U G C G –5’
Figure 7.47: Double stranded oligonucleotide A5B4.
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Figure 7.48: Fraction folded plot of A5B4.
Table 7.24: Tm and thermodynamic data of A5B4.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 52.2 51.4 50.0 48.6
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -14.0 -79.4 -219 0.985
1/T vs. ln Ka -14.0 ± 0.1 -78.5 ± 1.6 -216 ± 5
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7.25 Base pairing of A5B5
5’– C G C A U G C G U A C G C –3’
...
...
...
...
...
...
...
...
...
...
...
...
...
3’– G C G U A C C C A U G C G –5’
Figure 7.49: Double stranded oligonucleotide A5B5.
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Figure 7.50: Fraction folded plot of A5B5.
Table 7.25: Tm and thermodynamic data of A5B5.
Concentration [µM] 15.56 9.73 6.08 3.80
Tm [◦C] 49.4 48.0 46.8 45.4
∆G◦[kcal/mol] ∆H◦[kcal/mol] ∆S◦[cal/mol] R2
ln CTotal vs. 1/Tm -13.0 -73.5 -203 0.999
1/T vs. ln Ka -13.2 ± 0.2 -76.8 ± 1.0 -213 ± 3
Chapter 8
Crystallographic Data of
13α
Crystallised from CH2Cl2 / MeOH
Empirical formula C24H27N3O3
Formula weight [g mol−1] 405.49
Crystal colour, habit colourless, prism
Crystal dimensions [mm] 0.17 x 0.30 x 0.32
Temperature [K] 160(1)
Crystal system orthorhombic
Space group P212121 (#19)
Z 4
Reflections for cell determination 3568
2θ range for cell determination [◦] 4–60
Unit cell parameters a [A˚] 7.3020(1)
b [A˚] 12.6767(2)
c [A˚] 23.3601(4)
α [◦] 90
β [◦] 90
γ [◦] 90
V [A˚3] 2162.33(6)
F(000) 864
DX [g cm−1] 1.245
µ(Mo Kα) [mm−1] 0.0830
Scan type +
153
2θ(max) [◦] 60
Total reflections measured 29521
Symmetry independent reflections 3582
Rint 0.068
Reflections with I < 2σ(I) 3233
Reflections used in refinement 3582
Parameters refined 280
Final R(F) [I < 2σ(I) reflections] 0.0639
wR(F2) (all data) 0.1712
Weigths: w = [σ2(Fo2) + (0.1111P)2 + 0.5951P]−1 where P = (Fo2 + 2Fc2)/3
Goodness of fit 0.101
Final ∆max/σ 0.001
∆ρ (max; min) [e A˚−3] 0.38; -0.35
σ(dC−C [A˚] 0.003–0.006
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